ciprofloxacin has been researched along with Cross Infection in 297 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Cross Infection: Any infection which a patient contracts in a health-care institution.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective, cost-effectiveness analysis was performed on 106 clinically evaluable patients who participated in a multi-centre, randomized study of sequential IV/oral ciprofloxacin therapy versus ceftazidime for the treatment of nosocomial pneumonia." | 9.08 | Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. ( Paladino, JA, 1995) |
| "Intravenous ciprofloxacin and ceftazidime were compared for efficacy in the treatment of nosocomial pneumonia and urinary tract infection (UTI)." | 9.07 | Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. ( Billeter, M; Dempsey, RJ; Hatton, J; Rapp, RP; Tibbs, PA; Young, AB, 1991) |
| " In an ongoing study, 11 patients with nosocomial lower respiratory tract infections were given 200 mg of intravenous ciprofloxacin every 12 hours." | 9.06 | Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ( Cumbo, TJ; Fracasso, JE; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ; Vance, JW; Vari, AJ, 1987) |
| " Daptomycin shows a high efficacy against CNS, and it could be useful for the treatment of primary bacteremia or catheter associated bacteremia." | 7.77 | Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. ( Fajardo Olivares, M; Hidalgo Orozco, R; Robles Marcos, M; Rodríguez Garrido, S; Rodríguez-Vidigal, FF; Vera Tomé, A, 2011) |
| "Due to the high success rate, even in cases with failed antimicrobial pretreatment, and the favourable risk-benefit ratio of high-dose ciprofloxacin, ciprofloxacin appears to be an attractive choice in the empiric treatment of hospital-acquired pneumonia." | 7.71 | [Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients]. ( Kljucar, S; Landen, H; Rost, KL, 2002) |
| "Fifty patients with gram-negative lower respiratory tract infections were treated with intravenous ciprofloxacin to evaluate efficacy and safety." | 7.67 | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ( Cumbo, TJ; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ, 1989) |
| "Ciprofloxacin treatment is effective in life-threatening multi-drug-resistant P." | 5.32 | Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections. ( Belet, N; Haciömeroğlu, P; Küçüködük, S, 2004) |
| "Oral ciprofloxacin therapy was continued for 10 days and the patient remained free of symptoms with formed stools thereafter." | 5.29 | Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. ( Porco, FV; Visconte, EB, 1995) |
| "An open-label randomised clinical trial was designed to compare the efficacy and tolerance of levofloxacin and ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with high-risk neutropenia, and to monitor the emergence of antimicrobial resistance." | 5.12 | Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. ( Huijgens, PC; Janssen, JJ; Leidekker, ME; Simoons-Smit, AM; Timmers, GJ; Vandenbroucke-Grauls, CM, 2007) |
| "The efficacy of ciprofloxacin was studied in the treatment of 22 patients with hospital infection of the lower respiratory tract: 10 patients with nosocomial pneumonia, 8 with exacerbation of chronic obstructive bronchitis, 3 with exacerbation of mucoviscidosis and 1 with bronchiectasis." | 5.08 | [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. ( Avdeev, SN; Belevskiĭ, AS; Chuchalin, AG; Novikov, IuK, 1997) |
| "A retrospective, cost-effectiveness analysis was performed on 106 clinically evaluable patients who participated in a multi-centre, randomized study of sequential IV/oral ciprofloxacin therapy versus ceftazidime for the treatment of nosocomial pneumonia." | 5.08 | Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. ( Paladino, JA, 1995) |
| "Intravenous ciprofloxacin and ceftazidime were compared for efficacy in the treatment of nosocomial pneumonia and urinary tract infection (UTI)." | 5.07 | Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. ( Billeter, M; Dempsey, RJ; Hatton, J; Rapp, RP; Tibbs, PA; Young, AB, 1991) |
| " In an ongoing study, 11 patients with nosocomial lower respiratory tract infections were given 200 mg of intravenous ciprofloxacin every 12 hours." | 5.06 | Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. ( Cumbo, TJ; Fracasso, JE; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ; Vance, JW; Vari, AJ, 1987) |
| " In cystic fibrosis-associated acute exacerbations of chronic pseudomonal pneumonitis, the outcome of oral ciprofloxacin therapy was very satisfactory in the six major studies reported (approximately 85% improvement rates)." | 4.77 | Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. ( Bayer, AS, 1989) |
| " In general, strains were resistant to some of the antimicrobials most frequently used to treat Acinetobacter infections such as piperacillin-tazobactam (64." | 3.85 | Prevalence and antimicrobial susceptibility of Acinetobacter spp. isolated from meat. ( Carvalheira, A; Casquete, R; Silva, J; Teixeira, P, 2017) |
| " Treatment in indoor locations, presence of urinary catheters and pregnancy along with recent exposure to antibiotics especially fluoroquinolones, third generation cephalosporins and piperacillin-tazobactam were identified as independent risk factors." | 3.83 | Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India. ( Anupurba, S; Banerjee, T, 2016) |
| " Daptomycin shows a high efficacy against CNS, and it could be useful for the treatment of primary bacteremia or catheter associated bacteremia." | 3.77 | Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia. ( Fajardo Olivares, M; Hidalgo Orozco, R; Robles Marcos, M; Rodríguez Garrido, S; Rodríguez-Vidigal, FF; Vera Tomé, A, 2011) |
| "In vitro activities of colistin and other drugs were tested against 221 Klebsiella pneumoniae isolates that were collected between 2006 and 2007 in nine tertiary care South Korean hospitals from patients with bacteremia." | 3.76 | Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea. ( Chung, DR; Ko, KS; Peck, KR; Son, JS; Song, JH; Suh, JY, 2010) |
| "Due to the high success rate, even in cases with failed antimicrobial pretreatment, and the favourable risk-benefit ratio of high-dose ciprofloxacin, ciprofloxacin appears to be an attractive choice in the empiric treatment of hospital-acquired pneumonia." | 3.71 | [Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients]. ( Kljucar, S; Landen, H; Rost, KL, 2002) |
| "Food and Drug Administration regulations state that ciprofloxacin hydrochloride may cause arthropathies." | 3.70 | Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: efficacious or contraindicated? ( Desai, M; Edgar, P; Heggers, JP; Herndon, DN; John, SD; Klein, GL; Villarreal, C; Wolf, S, 1998) |
| "Ciprofloxacin was used as empirical therapy for peritonitis in patients receiving continuous ambulatory peritoneal dialysis (CAPD) for 26 months, providing an opportunity to study the epidemiology of ciprofloxacin resistance amongst coagulase-negative staphylococci (CNS)." | 3.68 | The epidemiology of ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients. ( Cookson, BD; Dryden, MS; McCann, M; Phillips, I; Talsania, H, 1992) |
| "Fifty patients with gram-negative lower respiratory tract infections were treated with intravenous ciprofloxacin to evaluate efficacy and safety." | 3.67 | Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. ( Cumbo, TJ; Nix, DE; Peloquin, CA; Sands, MF; Schentag, JJ, 1989) |
| "Children with hematological malignancies were divided into 2 groups according to the intensity of antibiotic treatment of infectious complications." | 2.82 | [Generation of Antibiotic Tolerant Bacterial Persisters in Immunocompromized Patients with Hematologic and Malignant Diseases: A New Problem of Health-Care Associated Infections]. ( Gaponov, AM; Gracheva, AN; Minaeva, NZ; Pisarev, VM; Solopova, GG; Tutelyan, AV, 2016) |
| "coli bacteremia were due to QREC." | 2.69 | Emergence and dissemination of quinolone-resistant Escherichia coli in the community. ( Coll, I; Garau, J; Gómez-Vera, JR; Llovet, T; Rodríguez-Carballeira, M; Ruíz-Bremón, A; Vidal, D; Xercavins, M, 1999) |
| "ciprofloxacin was at least equivalent to imipenem in terms of bacteriological eradication and clinical response." | 2.69 | Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia. ( Caldwell, JW; Johnson, RH; Singh, S, 1999) |
| "These superinfections occurred in mechanically ventilated, postoperative cardiac surgical patients after 13 days in the intensive care unit (ICU)." | 2.69 | Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study. ( Brase, R; Heimesaat, M; Kljucar, S; Manhold, C; Timm, J; von Pritzbuer, E; von Rolbicki, U, 1998) |
| " The once daily dosage of fleroxacin [400 mg once daily intravenously (i." | 2.68 | Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia. ( Marklein, G, 1996) |
| "pneumoniae was the most common isolate, followed by H." | 2.67 | A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. ( Gruninger, RP; Guay, DR; Hirata-Dulas, CA; Peterson, PK; Stein, DJ, 1991) |
| "For levofloxacin-treated CAP patients with P." | 2.43 | Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006) |
| "Several new approaches to treatment of pneumonia in the critical care setting are being evaluated, including single-agent empiric coverage using a broad-spectrum beta-lactam agent; broad-spectrum quinolones, such as ciprofloxacin; intrabronchial aminoglycoside instillation therapy; and passive immune therapy with immunoglobulins and monoclonal antibodies." | 2.38 | Approach to therapy of respiratory infections in the critical care setting. ( Pennington, JE, 1990) |
| " In this study, a panel of reference and clinical strains of major nosocomial pathogens were subjected to serial dosage cycles of silver and ciprofloxacin." | 1.62 | Repeated exposure of nosocomial pathogens to silver does not select for silver resistance but does impact ciprofloxacin susceptibility. ( Addison, O; Balacco, DL; Cox, SC; Grover, LM; Hall, T; Kuehne, SA; Lowther, M; Villapún, VM; Webber, MA, 2021) |
| "Post-URS sepsis was 7." | 1.56 | Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis. ( Amiel, GE; Badaan, S; Kastin, A; Kravtsov, A; Mullerad, M; Zisman, A, 2020) |
| "We report a case of pneumonic plague co-infected by a MDR-Stenotrophomonas maltophilia." | 1.48 | Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report. ( Andrianaivoarimanana, V; Bertherat, E; Rajaonarison, R; Rajerison, M; Rakotondramaro, T; Rogier, C, 2018) |
| "chelonae may be associated with nosocomial infections including catheter related sepsis, pneumonia etc." | 1.42 | Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host. ( Antony, SJ, 2015) |
| "Mass-related symptoms caused by hepatic cysts are effectively treated by aspiration sclerotherapy (AS)." | 1.40 | Hepatic cyst infection following aspiration sclerotherapy: a case series. ( Drenth, JP; Lantinga, MA; Wijnands, TF, 2014) |
| "Ertapenem was introduced in January 2005." | 1.39 | Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? ( Bou, G; Castelo-Corral, L; Gutiérrez-Urbón, JM; Llinares, P; López-Calviño, B; Molina, F; Sousa, D, 2013) |
| "Gentamicin was the most effective antibiotic against E." | 1.38 | Antimicrobial resistance pattern of gram-negative bacteria of nosocomial origin at a teaching hospital in the Islamic Republic of Iran. ( Alijani, B; Dashti-Khavidaki, S; Khalili, H; Safhami, S; Soltani, R, 2012) |
| "No cases of Clostridium difficile infection were recorded for any of these patients within 1 month of receiving antibiotics." | 1.37 | Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. ( Aliyu, SH; Doble, A; Madden, T; Neal, DE, 2011) |
| "Levofloxacin use was associated with increased resistance of P." | 1.36 | Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. ( Chun, CL; Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Sun, KL, 2010) |
| "Carbapenems were consistently the most active drugs tested." | 1.36 | Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob ( Badal, RE; Baquero, F; Bouchillon, SK; Cantón, R; Hawser, SP; Hoban, DJ, 2010) |
| " However, additional experiments are required to validate the robustness of this model after longer exposure periods and multiple dosing regimens, as well as in vivo." | 1.36 | Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa. ( Comets, E; Couet, W; Grégoire, N; Grignon, C; Marliat, M; Ploy, MC; Raherison, S, 2010) |
| "aeruginosa nosocomial infections, particularly those caused by multidrug-resistant isolates that emerge during antipseudomonal treatments." | 1.36 | Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. ( Ge, Y; Juan, C; Moya, B; Oliver, A; Pérez, JL; Zamorano, L, 2010) |
| "Ciprofloxacin resistance was observed only in hospital strains." | 1.35 | Bacillus cereus nosocomial infection from reused towels in Japan. ( Baranovich, T; Dohmae, S; Higuchi, W; Isobe, H; Itoh, M; Kobayashi, S; Okubo, T; Takano, T; Tanabe, Y; Uchiyama, M; Yamamoto, T, 2008) |
| "Since 2002, an epidemic of Clostridium difficile infections has occurred in southern Quebec, Canada." | 1.35 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. ( Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M, 2008) |
| "Levofloxacin use was more frequent in the QR P." | 1.33 | Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. ( Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG, 2006) |
| "Levofloxacin was added to the formulary in 1999, and gatifloxacin was substituted for levofloxacin in 2001." | 1.33 | Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. ( Bosso, JA; Mauldin, PD, 2006) |
| "Meropenem, imipenem, cefepime, ceftazidime (2 g every 8 hrs), and piperacillin/tazobactam have high probabilities of achieving adequate pharmacodynamic exposures when given for the empirical treatment of nosocomial pneumonia in the absence of methicillin-resistant S." | 1.33 | Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program. ( Kuti, JL; Nicolau, DP; Sun, HK, 2005) |
| "Ciprofloxacin treatment is effective in life-threatening multi-drug-resistant P." | 1.32 | Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections. ( Belet, N; Haciömeroğlu, P; Küçüködük, S, 2004) |
| "A patient with chronic lymphocytic leukemia developed a cutaneous infection with the clinical pattern of necrotizing otitis externa." | 1.32 | [Necrotizing otitis externa caused by Stenotrophomonas maltophilia]. ( Börner, D; Fischer, M; Marsch, WC, 2003) |
| "The incidence of nosocomial infections in patients after ICAAS fell from 78." | 1.32 | Prevention of nosocomial lower respiratory tract infections in patients after intracranial artery aneurysm surgery with a short course of antimicrobials. ( Beovic, B; Bosnjak, R; Cizman, M; Hergouth-Krizan, V; Matos, B; Mueller-Premru, M; Seme, K, 2003) |
| "coli bacteremia have not changed, yet the mortality was lower in our series." | 1.32 | [Bacteremia due to Escherichia coli: epidemiological analysis and sensitivity to antibiotics in a county hospital]. ( García-Somoza, D; Gudiol, F; Javaloyas, M, 2003) |
| "Ciprofloxacin appears to be a good therapeutic choice for the treatment of severe nosocomial infections in NICU." | 1.31 | [Nosocomial infections in neonatal and pediatric intensive care. The appeal of ciprofloxacin]. ( Benomar, S; Lahbabi, MS; Nejjari, N, 2000) |
| "Trovafloxacin was 2-4 times more active than ciprofloxacin against both groups of strains." | 1.31 | Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin. ( Blanco, MT; Gómez-García, AC; Hurtado, C; Morán, FJ; Pérez-Giraldo, C; Sánchez-Silos, RM, 2001) |
| "Ciprofloxacin and amikacin were somewhat more active than cephalosporins, but resistant isolates were also frequent." | 1.30 | Activity of selected beta-lactams, ciprofloxacin, and amikacin against different Acinetobacter baumannii biotypes from Chilean hospitals. ( Bello, H; Dominguez, M; Garcia, A; Gonzalez, G; Mella, S; Zemelman, R, 1997) |
| " coli develop in the presence of long-term selective ciprofloxacin pressure at a dosing regimen of 250 mg bid for more than 20 days and that treatment with a broad spectrum antimicrobial for more than three days favours the selection of multi-resistant E." | 1.30 | Molecular epidemiology of multi-resistant Escherichia coli. ( Barrett, SP; Cheasty, T; Guyot, A; Hampton, MD; Threlfall, EJ, 1999) |
| "Ciprofloxacin was given to all resident patients and to all affected staff." | 1.29 | Large scale use of ciprofloxacin in the control of a Salmonella outbreak in a hospital for the mentally handicapped. ( Dyson, C; Ribeiro, CD; Westmoreland, D, 1995) |
| "Oral ciprofloxacin therapy was continued for 10 days and the patient remained free of symptoms with formed stools thereafter." | 1.29 | Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin. ( Porco, FV; Visconte, EB, 1995) |
| "Ciprofloxacin has limited usefulness against MR Staphylococcus aureus but can be still used to treat Staphylococcus epidermidis infections." | 1.29 | Different susceptibility of coagulase-positive and coagulase-negative staphylococci to ciprofloxacin. ( Andreana, A; Florio, A; Locatelli, A; Rambaldi, A; Rosario, P; Tripodi, MF; Utili, R, 1996) |
| "Ciprofloxacin was the quinolone of choice in 24/32 (75%) of assessable cases." | 1.29 | An audit of ciprofloxacin use in a district general hospital. ( Fenelon, LE; MacGowan, AP; Reeves, DS; Smyth, EG; Speirs, GE; Speller, DC; Wilcox, MH, 1995) |
| "Ciprofloxacin was given at a dose of 200 mg over 30 min by using an automatic pump." | 1.29 | Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia. ( Bruguerolle, B; De Micco, P; Gouin, F; Mallet, MN; Martin, C; Papazian, L; Saux, P, 1994) |
| "Ciprofloxacin was withdrawn from use in the unit and daily bathing with chlorhexidine gluconate solution started." | 1.28 | Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. ( Burnie, JP; Hartley, JW; Lee, W; Oppenheim, BA, 1989) |
| "Ciprofloxacin was given at a dose of 3 mg/kg over 30 min." | 1.28 | [Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients]. ( Bruguerolle, B; Gouin, F; Mallet, MN; Martin, C; Papazian, L; Portet, C; Saux, P, 1991) |
| " The pharmacokinetic profile of the drug was then superimposed on the bacterial MIC, and we then derived the patients individual peak to MIC ratio, area above MIC, and time above MIC." | 1.28 | Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. ( Schentag, JJ, 1990) |
| "Ciprofloxacin was the most potent antibiotic and had the broadest spectrum of activity (98% of isolates susceptible, MIC90 range: 0." | 1.28 | Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency. ( Mori, M; Pfaller, MA; Stanley, GL; Wenzel, RP, 1989) |
| "Ciprofloxacin was administered intravenously, either 400 mg every 12 hours or, after a loading dose of 600 mg every 12 hours on Day 1, 400 mg every 12 hours on successive treatment days." | 1.28 | Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections. ( Beermann, D; Heimesaat, M; Kljucar, S; Scholl, H; Timm, J; von Pritzbuer, E, 1989) |
| "Ciprofloxacin was given twice a day, as 500 mg through a gastric tube or 200 mg intravenously, and both applications led to negative cultures for aerobic Gram-negative bacilli from faeces and throat, except for a few periods of carriage lasting only a few days." | 1.28 | Prophylaxis of respiratory tract infection in patients on artificial respiration. ( Haverkorn, MJ, 1989) |
| "Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n = 14), the MIC90 values being 0." | 1.28 | Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. ( Bale, MJ; Doebbeling, BN; Pfaller, MA; Wenzel, RP, 1990) |
| " The terminal half-life was 4." | 1.28 | Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ( Arich, C; Beziau, H; Bressolle, F; Fabre, D; Galtier, M; Gomeni, R; Lemesle, F, 1991) |
| "Ciprofloxacin was used successfully in two outbreaks of salmonella gastroenteritis at a dose of 500 mg bd orally for seven days." | 1.28 | Management of institutional outbreaks of Salmonella gastroenteritis. ( Ahmad, F; Cowden, J; Lightfoot, NF, 1990) |
| "Ciprofloxacin was generally 2-4 fold less active against aminoglycoside-resistant isolates than against their aminoglycoside-susceptible counterparts." | 1.27 | In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics. ( Delzell, D; Kabins, SA; Nathan, C; Weinstein, RA, 1987) |
| "Seventeen patients with staphylococcal infections severe enough to require hospital admission and initial parenteral therapy were treated with ciprofloxacin; the results were poor, with clinical failure in five and bacteriological failure in 12." | 1.27 | Ciprofloxacin treatment of Staphylococcus aureus infections. ( Righter, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (4.71) | 18.7374 |
| 1990's | 83 (27.95) | 18.2507 |
| 2000's | 103 (34.68) | 29.6817 |
| 2010's | 79 (26.60) | 24.3611 |
| 2020's | 18 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Mendonça, N | 1 |
| Leitão, J | 1 |
| Manageiro, V | 1 |
| Ferreira, E | 1 |
| Caniça, M | 1 |
| Tumbarello, M | 1 |
| Sanguinetti, M | 1 |
| Montuori, E | 1 |
| Trecarichi, EM | 1 |
| Posteraro, B | 1 |
| Fiori, B | 1 |
| Citton, R | 1 |
| D'Inzeo, T | 1 |
| Fadda, G | 1 |
| Cauda, R | 1 |
| Spanu, T | 1 |
| Endimiani, A | 1 |
| Luzzaro, F | 1 |
| Migliavacca, R | 1 |
| Mantengoli, E | 1 |
| Hujer, AM | 1 |
| Hujer, KM | 1 |
| Pagani, L | 1 |
| Bonomo, RA | 1 |
| Rossolini, GM | 1 |
| Toniolo, A | 1 |
| Daikos, GL | 1 |
| Kosmidis, C | 1 |
| Tassios, PT | 1 |
| Petrikkos, G | 1 |
| Vasilakopoulou, A | 1 |
| Psychogiou, M | 1 |
| Stefanou, I | 1 |
| Avlami, A | 1 |
| Katsilambros, N | 1 |
| Mendes, RE | 1 |
| Castanheira, M | 1 |
| Toleman, MA | 1 |
| Sader, HS | 3 |
| Jones, RN | 4 |
| Walsh, TR | 1 |
| Simor, AE | 1 |
| Stuart, TL | 1 |
| Louie, L | 1 |
| Watt, C | 1 |
| Ofner-Agostini, M | 1 |
| Gravel, D | 1 |
| Mulvey, M | 1 |
| Loeb, M | 1 |
| McGeer, A | 2 |
| Bryce, E | 1 |
| Matlow, A | 1 |
| Wang, H | 4 |
| Guo, P | 1 |
| Sun, H | 3 |
| Yang, Q | 3 |
| Chen, M | 4 |
| Xu, Y | 3 |
| Zhu, Y | 1 |
| Gutiérrez, O | 1 |
| Juan, C | 3 |
| Cercenado, E | 1 |
| Navarro, F | 1 |
| Bouza, E | 1 |
| Coll, P | 1 |
| Pérez, JL | 2 |
| Oliver, A | 3 |
| Quiroga, MP | 1 |
| Andres, P | 1 |
| Petroni, A | 1 |
| Soler Bistué, AJ | 1 |
| Guerriero, L | 1 |
| Vargas, LJ | 1 |
| Zorreguieta, A | 1 |
| Tokumoto, M | 1 |
| Quiroga, C | 1 |
| Tolmasky, ME | 1 |
| Galas, M | 1 |
| Centrón, D | 1 |
| Garza-Ramos, U | 2 |
| Morfin-Otero, R | 1 |
| Hernández, E | 1 |
| Rodriguez-Noriega, E | 1 |
| Sanchez, A | 1 |
| Carrillo, B | 1 |
| Esparza-Ahumada, S | 1 |
| Silva-Sanchez, J | 2 |
| Carrër, A | 1 |
| Poirel, L | 1 |
| Eraksoy, H | 1 |
| Cagatay, AA | 1 |
| Badur, S | 1 |
| Nordmann, P | 1 |
| Labbé, AC | 1 |
| Poirier, L | 1 |
| Maccannell, D | 1 |
| Louie, T | 1 |
| Savoie, M | 1 |
| Béliveau, C | 1 |
| Laverdière, M | 1 |
| Pépin, J | 1 |
| Zarrilli, R | 1 |
| Vitale, D | 1 |
| Di Popolo, A | 1 |
| Bagattini, M | 1 |
| Daoud, Z | 1 |
| Khan, AU | 1 |
| Afif, C | 1 |
| Triassi, M | 1 |
| Adams-Haduch, JM | 1 |
| Paterson, DL | 2 |
| Sidjabat, HE | 1 |
| Pasculle, AW | 1 |
| Potoski, BA | 1 |
| Muto, CA | 1 |
| Harrison, LH | 1 |
| Doi, Y | 1 |
| Zheng, B | 1 |
| Tomita, H | 1 |
| Inoue, T | 1 |
| Ike, Y | 1 |
| Liu, Y | 1 |
| Du, N | 1 |
| Shen, E | 1 |
| Chen, H | 2 |
| Niu, J | 1 |
| Ye, H | 1 |
| Prakash, V | 1 |
| Lewis, JS | 1 |
| Herrera, ML | 1 |
| Wickes, BL | 1 |
| Jorgensen, JH | 1 |
| Viedma, E | 1 |
| Acosta, J | 1 |
| Zamorano, L | 2 |
| Otero, JR | 1 |
| Sanz, F | 1 |
| Chaves, F | 1 |
| Suh, JY | 1 |
| Son, JS | 1 |
| Chung, DR | 1 |
| Peck, KR | 1 |
| Ko, KS | 1 |
| Song, JH | 1 |
| Haebich, D | 1 |
| Kroll, HP | 1 |
| Lerchen, HG | 1 |
| Bulik, CC | 1 |
| Christensen, H | 1 |
| Nicolau, DP | 2 |
| Moya, B | 1 |
| Ge, Y | 1 |
| Grégoire, N | 1 |
| Raherison, S | 1 |
| Grignon, C | 1 |
| Comets, E | 1 |
| Marliat, M | 1 |
| Ploy, MC | 1 |
| Couet, W | 1 |
| Hawser, SP | 1 |
| Bouchillon, SK | 1 |
| Hoban, DJ | 1 |
| Badal, RE | 2 |
| Cantón, R | 1 |
| Baquero, F | 1 |
| Wang, Y | 4 |
| Shi, X | 1 |
| Zhang, J | 1 |
| Lv, Y | 1 |
| Du, X | 1 |
| ChaoLuMen, Q | 1 |
| Wang, J | 1 |
| Khosravi, AD | 1 |
| Montazeri, EA | 1 |
| Maki, SR | 1 |
| Coombs, GW | 4 |
| Daley, DA | 4 |
| Yee, NWT | 1 |
| Shoby, P | 4 |
| Mowlaboccus, S | 4 |
| Zannat, KE | 3 |
| Ahmed, AU | 1 |
| Tanzim, SM | 3 |
| Ahmed, SM | 1 |
| Afrin, A | 3 |
| Saha, BC | 3 |
| Joynal, JB | 3 |
| Khanam, TA | 1 |
| Nira, NH | 2 |
| Saha, SK | 1 |
| Aktar, M | 1 |
| Akhter, N | 1 |
| Hossain, MA | 1 |
| Cummings, KJ | 1 |
| Siler, JD | 1 |
| Goodman, LB | 1 |
| Childs-Sanford, SE | 1 |
| Rimaz, S | 1 |
| Tajzadeh, P | 1 |
| Bahrami, M | 1 |
| Nooghabi, M | 1 |
| Eshrati, B | 1 |
| Effati, S | 1 |
| Yaghoobi, M | 1 |
| Zisman, A | 1 |
| Badaan, S | 1 |
| Kastin, A | 1 |
| Kravtsov, A | 1 |
| Amiel, GE | 1 |
| Mullerad, M | 1 |
| Kotb, DN | 1 |
| Mahdy, WK | 1 |
| Mahmoud, MS | 2 |
| Khairy, RMM | 2 |
| Shady, RR | 1 |
| Esmail, MAM | 1 |
| Attia, NM | 1 |
| Elbaradei, A | 1 |
| Mohammed, MA | 1 |
| Ahmed, MT | 1 |
| Anwer, BE | 1 |
| Aboshanab, KM | 1 |
| Aboulwafa, MM | 1 |
| Khuntayaporn, P | 1 |
| Kanathum, P | 1 |
| Houngsaitong, J | 1 |
| Montakantikul, P | 1 |
| Thirapanmethee, K | 1 |
| Chomnawang, MT | 1 |
| Dos Santos, LDR | 1 |
| Furlan, JPR | 1 |
| Gallo, IFL | 1 |
| Ramos, MS | 1 |
| Savazzi, EA | 1 |
| Stehling, EG | 1 |
| Villapún, VM | 1 |
| Balacco, DL | 1 |
| Webber, MA | 1 |
| Hall, T | 1 |
| Lowther, M | 1 |
| Addison, O | 1 |
| Kuehne, SA | 1 |
| Grover, LM | 1 |
| Cox, SC | 1 |
| Valcarcel, B | 1 |
| De-la-Cruz-Ku, G | 1 |
| Malpica, L | 1 |
| Enriquez-Vera, D | 1 |
| Ferrone, V | 3 |
| Carlucci, M | 3 |
| Cotellese, R | 3 |
| Raimondi, P | 3 |
| Cichella, A | 3 |
| Di Marco, L | 1 |
| Genovese, S | 1 |
| Carlucci, G | 3 |
| Chen, CH | 1 |
| Lin, CH | 1 |
| Lin, JS | 1 |
| Bosch-Nicolau, P | 1 |
| Falcó, V | 1 |
| Viñado, B | 1 |
| Andreu, A | 1 |
| Len, O | 1 |
| Almirante, B | 2 |
| Pigrau, C | 2 |
| Kumar, K | 1 |
| Chen, J | 1 |
| Drlica, K | 1 |
| Shopsin, B | 1 |
| Tutelyan, AV | 1 |
| Pisarev, VM | 1 |
| Minaeva, NZ | 2 |
| Gaponov, AM | 1 |
| Gracheva, AN | 1 |
| Solopova, GG | 1 |
| Hawkey, J | 1 |
| Ascher, DB | 1 |
| Judd, LM | 1 |
| Wick, RR | 1 |
| Kostoulias, X | 1 |
| Cleland, H | 1 |
| Spelman, DW | 1 |
| Padiglione, A | 1 |
| Peleg, AY | 1 |
| Holt, KE | 1 |
| Rahdar, HA | 1 |
| Kazemian, H | 1 |
| Bimanand, L | 1 |
| Shahraki-Zahedani, S | 1 |
| Feyisa, SG | 1 |
| Taki, E | 1 |
| Havaei, SA | 1 |
| Karami-Zarandi, M | 1 |
| Andrianaivoarimanana, V | 1 |
| Bertherat, E | 1 |
| Rajaonarison, R | 1 |
| Rakotondramaro, T | 1 |
| Rogier, C | 1 |
| Rajerison, M | 1 |
| Palumbo, P | 1 |
| Freitas, EA | 1 |
| Ferreira, WA | 1 |
| Filho, RAAB | 1 |
| Oliveira, CMC | 1 |
| Dhyani, A | 1 |
| Silva, LM | 1 |
| Fraiji, NA | 1 |
| Ferreira, CM | 1 |
| Chávez-Jacobo, VM | 1 |
| Hernández-Ramírez, KC | 1 |
| Barrios-Camacho, H | 1 |
| Ortiz-Alvarado, R | 1 |
| Cervantes, C | 1 |
| Meza-Carmen, V | 1 |
| Ramírez-Díaz, MI | 1 |
| Royer, G | 1 |
| Fourreau, F | 1 |
| Boulanger, B | 1 |
| Mercier-Darty, M | 1 |
| Ducellier, D | 1 |
| Cizeau, F | 1 |
| Potron, A | 1 |
| Podglajen, I | 1 |
| Mongardon, N | 1 |
| Decousser, JW | 1 |
| Sousa, D | 1 |
| Castelo-Corral, L | 1 |
| Gutiérrez-Urbón, JM | 1 |
| Molina, F | 1 |
| López-Calviño, B | 1 |
| Bou, G | 1 |
| Llinares, P | 1 |
| Rimbara, E | 1 |
| Mori, S | 1 |
| Kim, H | 1 |
| Matsui, M | 1 |
| Suzuki, S | 1 |
| Takahashi, S | 1 |
| Yamamoto, S | 1 |
| Mukai, M | 1 |
| Shibayama, K | 1 |
| Tansarli, GS | 1 |
| Athanasiou, S | 1 |
| Falagas, ME | 2 |
| Saiful Anuar, AS | 1 |
| Mohd Yusof, MY | 1 |
| Tay, ST | 1 |
| Virok, DP | 1 |
| Ábrók, M | 1 |
| Szél, B | 1 |
| Tajti, Z | 1 |
| Mader, K | 1 |
| Urbán, E | 1 |
| Tálosi, G | 1 |
| Bozkurt-Guzel, C | 1 |
| Savage, PB | 1 |
| Akcali, A | 1 |
| Ozbek-Celik, B | 1 |
| Izzo, I | 1 |
| Lania, D | 1 |
| Castro, A | 1 |
| Lanzini, F | 1 |
| Bella, D | 1 |
| Pagani, A | 1 |
| Colombini, P | 1 |
| MacFadden, DR | 1 |
| Ridgway, JP | 1 |
| Robicsek, A | 1 |
| Elligsen, M | 1 |
| Daneman, N | 1 |
| Büchler, AC | 1 |
| Rampini, SK | 1 |
| Stelling, S | 1 |
| Ledergerber, B | 1 |
| Peter, S | 1 |
| Schweiger, A | 1 |
| Ruef, C | 1 |
| Zbinden, R | 1 |
| Speck, RF | 1 |
| Wijnands, TF | 1 |
| Lantinga, MA | 1 |
| Drenth, JP | 1 |
| Al-Busaidi, I | 1 |
| Leis, JA | 1 |
| Gold, WL | 1 |
| Toi, A | 1 |
| Guo, W | 1 |
| He, Q | 1 |
| Wang, Z | 1 |
| Wei, M | 1 |
| Yang, Z | 1 |
| Du, Y | 1 |
| Wu, C | 1 |
| He, J | 1 |
| Sarma, JB | 1 |
| Marshall, B | 1 |
| Cleeve, V | 1 |
| Tate, D | 1 |
| Oswald, T | 1 |
| Woolfrey, S | 1 |
| Lee, CH | 1 |
| Su, TY | 1 |
| Ye, JJ | 1 |
| Hsu, PC | 1 |
| Kuo, AJ | 1 |
| Chia, JH | 2 |
| Lee, MH | 1 |
| Antony, SJ | 1 |
| Rosé, L | 1 |
| Coulter, MM | 1 |
| Chan, S | 1 |
| Hossain, J | 1 |
| Di Pentima, MC | 1 |
| Umezawa, K | 1 |
| Asai, S | 1 |
| Ohshima, T | 1 |
| Iwashita, H | 1 |
| Ohashi, M | 1 |
| Sasaki, M | 1 |
| Kaneko, A | 1 |
| Inokuchi, S | 1 |
| Miyachi, H | 1 |
| Zhang, H | 1 |
| Liao, K | 1 |
| Ni, Y | 1 |
| Yu, Y | 1 |
| Hu, B | 1 |
| Sun, Z | 1 |
| Huang, W | 1 |
| Wu, A | 1 |
| Feng, X | 1 |
| Luo, Y | 1 |
| Hu, Z | 1 |
| Chu, Y | 1 |
| Chen, S | 1 |
| Cao, B | 1 |
| Su, J | 1 |
| Gui, B | 1 |
| Duan, Q | 1 |
| Zhang, S | 1 |
| Shao, H | 1 |
| Kong, H | 1 |
| Hamad, T | 1 |
| Hellmark, B | 1 |
| Nilsdotter-Augustinsson, Å | 1 |
| Söderquist, B | 1 |
| Yayan, J | 1 |
| Ghebremedhin, B | 1 |
| Rasche, K | 1 |
| Gau, JS | 1 |
| Lin, WP | 1 |
| Kuo, LC | 1 |
| Hu, MK | 1 |
| Güler, G | 1 |
| Eraç, B | 1 |
| Aracil-García, B | 1 |
| Oteo-Iglesias, J | 1 |
| Cuevas-Lobato, Ó | 1 |
| Lara-Fuella, N | 1 |
| Pérez-Grajera, I | 1 |
| Fernández-Romero, S | 1 |
| Pérez-Vázquez, M | 1 |
| Campos, J | 1 |
| Mellmann, A | 1 |
| Bletz, S | 1 |
| Böking, T | 1 |
| Kipp, F | 1 |
| Becker, K | 1 |
| Schultes, A | 1 |
| Prior, K | 1 |
| Harmsen, D | 1 |
| Padhi, JR | 1 |
| Nayak, D | 1 |
| Nanda, A | 1 |
| Rauta, PR | 1 |
| Ashe, S | 1 |
| Nayak, B | 1 |
| Zycinska, K | 1 |
| Chmielewska, M | 1 |
| Lenartowicz, B | 1 |
| Hadzik-Blaszczyk, M | 1 |
| Cieplak, M | 1 |
| Kur, Z | 1 |
| Krupa, R | 1 |
| Wardyn, KA | 1 |
| Biglari, S | 1 |
| Hanafiah, A | 1 |
| Mohd Puzi, S | 1 |
| Ramli, R | 1 |
| Rahman, M | 2 |
| Lopes, BS | 1 |
| Lutz, P | 1 |
| Nischalke, HD | 1 |
| Krämer, B | 1 |
| Goeser, F | 1 |
| Kaczmarek, DJ | 1 |
| Schlabe, S | 1 |
| Parcina, M | 1 |
| Nattermann, J | 1 |
| Hoerauf, A | 1 |
| Strassburg, CP | 1 |
| Spengler, U | 1 |
| Carvalheira, A | 1 |
| Casquete, R | 1 |
| Silva, J | 1 |
| Teixeira, P | 1 |
| Marco, LD | 1 |
| Banerjee, T | 1 |
| Anupurba, S | 1 |
| Cook, PP | 3 |
| Das, TD | 1 |
| Gooch, M | 3 |
| Catrou, PG | 1 |
| Dohmae, S | 1 |
| Okubo, T | 1 |
| Higuchi, W | 1 |
| Takano, T | 1 |
| Isobe, H | 1 |
| Baranovich, T | 1 |
| Kobayashi, S | 1 |
| Uchiyama, M | 1 |
| Tanabe, Y | 1 |
| Itoh, M | 1 |
| Yamamoto, T | 1 |
| Damjanova, I | 1 |
| Tóth, A | 1 |
| Pászti, J | 1 |
| Hajbel-Vékony, G | 1 |
| Jakab, M | 1 |
| Berta, J | 1 |
| Milch, H | 1 |
| Füzi, M | 1 |
| Aldeyab, MA | 1 |
| Hughes, CM | 1 |
| Kearney, MP | 1 |
| Scott, MG | 1 |
| McDowell, DA | 1 |
| Hanley, J | 1 |
| McMahon, MA | 1 |
| Elshibly, SM | 1 |
| Bailie, R | 1 |
| McElnay, JC | 1 |
| Ogbolu, DO | 1 |
| Ogunledun, A | 1 |
| Adebiyi, OE | 1 |
| Daini, OA | 1 |
| Alli, AO | 1 |
| Terry, AO | 1 |
| Passerini de Rossi, B | 1 |
| García, C | 1 |
| Calenda, M | 1 |
| Vay, C | 1 |
| Franco, M | 1 |
| Sundram, F | 1 |
| Guyot, A | 2 |
| Carboo, I | 1 |
| Green, S | 1 |
| Lilaonitkul, M | 1 |
| Scourfield, A | 1 |
| Amábile-Cuevas, CF | 1 |
| Arredondo-García, JL | 1 |
| Cruz, A | 1 |
| Rosas, I | 1 |
| Hosgor-Limoncu, M | 1 |
| Ermertcan, S | 1 |
| Tasli, H | 1 |
| Yurtman, AN | 1 |
| Slim, E | 1 |
| Smit, CA | 1 |
| Bos, AJ | 1 |
| Peerbooms, PG | 1 |
| Oostdijk, EA | 1 |
| de Smet, AM | 1 |
| Blok, HE | 1 |
| Thieme Groen, ES | 1 |
| van Asselt, GJ | 1 |
| Benus, RF | 1 |
| Bernards, SA | 1 |
| Frénay, IH | 1 |
| Jansz, AR | 1 |
| de Jongh, BM | 1 |
| Kaan, JA | 1 |
| Leverstein-van Hall, MA | 1 |
| Mascini, EM | 1 |
| Pauw, W | 1 |
| Sturm, PD | 1 |
| Thijsen, SF | 1 |
| Kluytmans, JA | 1 |
| Bonten, MJ | 2 |
| Lee, YJ | 1 |
| Liu, HY | 1 |
| Lin, YC | 1 |
| Sun, KL | 1 |
| Chun, CL | 1 |
| Hsueh, PR | 4 |
| Chiu, CH | 1 |
| Lee, HY | 1 |
| Tseng, LY | 1 |
| Chen, CL | 1 |
| Su, LH | 1 |
| Liu, SY | 1 |
| Lai, CC | 2 |
| Tan, CK | 1 |
| Chou, CH | 1 |
| Hsu, HL | 1 |
| Huang, YT | 1 |
| Liao, CH | 1 |
| Tan, SH | 1 |
| Lawler, J | 1 |
| Foster, K | 1 |
| Hall, L | 1 |
| Talbot, D | 1 |
| Torpey, N | 1 |
| Raza, M | 1 |
| Gould, FK | 1 |
| Piekarska, K | 1 |
| Zacharczuk, K | 1 |
| Szych, J | 1 |
| Zawidzka, E | 1 |
| Wilk, E | 1 |
| Wardak, S | 1 |
| Jagielski, M | 1 |
| Gierczyński, R | 1 |
| Barbier, F | 1 |
| Wolff, M | 1 |
| Miliani, K | 1 |
| L'Hériteau, F | 1 |
| Lacavé, L | 1 |
| Carbonne, A | 1 |
| Astagneau, P | 1 |
| Wang, EW | 1 |
| Warren, DK | 2 |
| Ferris, VM | 1 |
| Casabar, E | 1 |
| Nussenbaum, B | 1 |
| Crivellaro, S | 1 |
| Leone, I | 1 |
| Bianco, O | 1 |
| Savoia, D | 1 |
| Weng, TC | 1 |
| Chen, YH | 1 |
| Lee, CC | 1 |
| Wang, CY | 1 |
| Tang, HJ | 1 |
| Ko, WC | 2 |
| Madden, T | 1 |
| Doble, A | 1 |
| Aliyu, SH | 1 |
| Neal, DE | 1 |
| Fajardo Olivares, M | 1 |
| Hidalgo Orozco, R | 1 |
| Rodríguez Garrido, S | 1 |
| Rodríguez-Vidigal, FF | 1 |
| Vera Tomé, A | 1 |
| Robles Marcos, M | 1 |
| Kuwabara, M | 1 |
| Kusano, N | 1 |
| Shimizu, E | 1 |
| Shimizu, W | 1 |
| Kobayashi, K | 1 |
| Koda, S | 1 |
| Doi, M | 1 |
| Sugai, M | 1 |
| Kumon, H | 1 |
| Ktari, S | 1 |
| Mnif, B | 1 |
| Koubaa, M | 1 |
| Mahjoubi, F | 1 |
| Ben Jemaa, M | 1 |
| Mhiri, MN | 1 |
| Hammami, A | 1 |
| Haenni, M | 1 |
| Ponsin, C | 1 |
| Métayer, V | 1 |
| Médaille, C | 1 |
| Madec, JY | 1 |
| Fadli, M | 1 |
| Saad, A | 1 |
| Sayadi, S | 1 |
| Chevalier, J | 1 |
| Mezrioui, NE | 1 |
| Pagès, JM | 1 |
| Hassani, L | 1 |
| Hu, YY | 1 |
| Cai, JC | 1 |
| Zhang, R | 1 |
| Zhou, HW | 1 |
| Sun, Q | 1 |
| Chen, GX | 1 |
| Medina Presentado, JC | 1 |
| Paciel López, D | 1 |
| Berro Castiglioni, M | 1 |
| Gerez, J | 1 |
| Issaoui, S | 1 |
| Maoulainine, FM | 1 |
| Elidrissi, NS | 1 |
| Sorra, N | 1 |
| Chabaa, L | 1 |
| Aboussad, A | 1 |
| Lewis, GJ | 1 |
| Fang, X | 1 |
| Caramia, G | 1 |
| Ruffini, E | 1 |
| Elgorriaga-Islas, E | 1 |
| Guggiana-Nilo, P | 1 |
| Domínguez-Yévenes, M | 1 |
| González-Rocha, G | 1 |
| Mella-Montecinos, S | 1 |
| Labarca-Labarca, J | 1 |
| García-Cañete, P | 1 |
| Bello-Toledo, H | 1 |
| Khalili, H | 1 |
| Soltani, R | 1 |
| Safhami, S | 1 |
| Dashti-Khavidaki, S | 1 |
| Alijani, B | 1 |
| Samonis, G | 1 |
| Karageorgopoulos, DE | 1 |
| Maraki, S | 1 |
| Levis, P | 1 |
| Dimopoulou, D | 1 |
| Spernovasilis, NA | 1 |
| Kofteridis, DP | 1 |
| Ma, Y | 1 |
| Jones, JE | 1 |
| Ritts, AC | 1 |
| Yu, Q | 1 |
| Dancer, SJ | 1 |
| Kirkpatrick, P | 1 |
| Corcoran, DS | 1 |
| Christison, F | 1 |
| Farmer, D | 1 |
| Robertson, C | 1 |
| Oren, I | 1 |
| Zuckerman, T | 1 |
| Avivi, I | 1 |
| Finkelstein, R | 1 |
| Yigla, M | 1 |
| Rowe, JM | 1 |
| Kljucar, S | 3 |
| Rost, KL | 1 |
| Landen, H | 1 |
| Thomas, C | 1 |
| Golledge, CL | 1 |
| Riley, TV | 1 |
| Bermejo, J | 1 |
| Lesnaberes, P | 1 |
| Arnesi, N | 1 |
| Gianello, M | 1 |
| Notario, R | 1 |
| Borda, N | 1 |
| Gambandé, T | 1 |
| Bencomo, B | 1 |
| Neuhauser, MM | 1 |
| Weinstein, RA | 2 |
| Rydman, R | 1 |
| Danziger, LH | 1 |
| Karam, G | 1 |
| Quinn, JP | 2 |
| Javaloyas, M | 1 |
| García-Somoza, D | 1 |
| Gudiol, F | 1 |
| Donnenfeld, ED | 1 |
| O'Brien, TP | 1 |
| Solomon, R | 1 |
| Perry, HD | 1 |
| Speaker, MG | 1 |
| Wittpenn, J | 1 |
| Vitkauskiene, A | 1 |
| Sakalauskas, R | 1 |
| Dudzevicius, V | 1 |
| Nejjari, N | 2 |
| Zerhouni, F | 1 |
| Bouharrou, A | 1 |
| Habzi, A | 1 |
| Najdi, T | 1 |
| Lahbabi, M | 1 |
| Benomar, S | 2 |
| West, M | 1 |
| Boulanger, BR | 1 |
| Fogarty, C | 1 |
| Tennenberg, A | 1 |
| Wiesinger, B | 1 |
| Oross, M | 1 |
| Wu, SC | 2 |
| Fowler, C | 1 |
| Morgan, N | 1 |
| Kahn, JB | 1 |
| Bruins, MJ | 1 |
| Fernandes, TM | 1 |
| Ruijs, GJ | 1 |
| Wolfhagen, MJ | 1 |
| van Rijn-van Berkel, JM | 1 |
| Schenk, BE | 1 |
| van Duynhoven, YT | 1 |
| Toraman, ZA | 1 |
| Yakupogullari, Y | 1 |
| Beovic, B | 1 |
| Matos, B | 1 |
| Bosnjak, R | 1 |
| Seme, K | 1 |
| Mueller-Premru, M | 1 |
| Hergouth-Krizan, V | 1 |
| Cizman, M | 1 |
| Brito, DV | 1 |
| Oliveira, EJ | 1 |
| Matos, C | 1 |
| Abdallah, VO | 1 |
| Gontijo Filho, PP | 1 |
| Börner, D | 1 |
| Marsch, WC | 1 |
| Fischer, M | 1 |
| Peters, HJ | 1 |
| Breitling, P | 1 |
| Iversen, A | 1 |
| Kühn, I | 1 |
| Franklin, A | 1 |
| Burman, LG | 1 |
| Olsson-Liljequist, B | 1 |
| Torell, E | 1 |
| Möllby, R | 1 |
| Weber, SG | 2 |
| Gold, HS | 1 |
| Hooper, DC | 1 |
| Karchmer, AW | 1 |
| Carmeli, Y | 2 |
| Belet, N | 1 |
| Haciömeroğlu, P | 1 |
| Küçüködük, S | 1 |
| Talon, D | 1 |
| Lallemand-De-Conto, S | 1 |
| Thouverez, M | 1 |
| Bertrand, X | 1 |
| Teng, LJ | 1 |
| Chen, WH | 1 |
| Pan, HJ | 1 |
| Chen, ML | 1 |
| Chang, SC | 1 |
| Luh, KT | 1 |
| Lin, FY | 1 |
| Naber, KG | 1 |
| Perera, S | 1 |
| Palasuntheram, C | 1 |
| Friedland, I | 1 |
| Gallagher, G | 1 |
| King, T | 1 |
| Woods, GL | 1 |
| Otağ, F | 1 |
| Ersöz, G | 1 |
| Salcioğlu, M | 1 |
| Bal, C | 1 |
| Schneider, I | 1 |
| Bauernfeind, A | 1 |
| Aubert, G | 1 |
| Carricajo, A | 1 |
| Vautrin, AC | 1 |
| Guyomarc'h, S | 1 |
| Fonsale, N | 1 |
| Page, D | 1 |
| Brunel, P | 1 |
| Rusch, P | 1 |
| Zéni, F | 1 |
| Díaz, PQ | 1 |
| Bello, HT | 1 |
| Domínguez, MY | 1 |
| Trabal, NF | 1 |
| Mella, SM | 1 |
| Zemelman, RZ | 1 |
| González, GR | 1 |
| Shorr, AF | 1 |
| Susla, GB | 1 |
| Kollef, MH | 1 |
| Okimoto, N | 1 |
| Yamato, K | 1 |
| Honda, Y | 1 |
| Kurihara, T | 1 |
| Osaki, K | 1 |
| Asaoka, N | 1 |
| Fujita, K | 1 |
| Ohba, H | 1 |
| Tumah, H | 1 |
| Meyer, E | 2 |
| Schwab, F | 2 |
| Jonas, D | 2 |
| Ruden, H | 1 |
| Gastmeier, P | 1 |
| Daschner, FD | 1 |
| Ray, GT | 1 |
| Baxter, R | 1 |
| DeLorenze, GN | 1 |
| Sun, HK | 1 |
| Kuti, JL | 1 |
| Dareau, S | 1 |
| Eledjam, JJ | 1 |
| Gros, T | 1 |
| Delire, V | 1 |
| Causse, L | 1 |
| Javitary, W | 1 |
| Bassoul, B | 1 |
| Leavis, HL | 1 |
| Willems, RJ | 1 |
| Top, J | 1 |
| Fernandez-Hidalgo, N | 1 |
| Calleja, R | 1 |
| Ruiz, I | 1 |
| Planes, AM | 1 |
| Rodriguez, D | 1 |
| Pahissa, A | 1 |
| Tennenberg, AM | 1 |
| Davis, NB | 1 |
| Kahn, J | 1 |
| Bosso, JA | 1 |
| Mauldin, PD | 1 |
| Kaye, KS | 2 |
| Kanafani, ZA | 1 |
| Dodds, AE | 1 |
| Engemann, JJ | 1 |
| Minaev, VI | 1 |
| Sokolov, AA | 1 |
| Avilova, ND | 1 |
| Mitrokhin, SD | 1 |
| Song, JY | 1 |
| Jung, SJ | 1 |
| Park, CW | 1 |
| Sohn, JW | 1 |
| Kim, WJ | 1 |
| Kim, MJ | 1 |
| Cheong, HJ | 1 |
| Kang, CI | 1 |
| Kim, SH | 1 |
| Bang, JW | 1 |
| Kim, HB | 1 |
| Kim, NJ | 1 |
| Kim, EC | 1 |
| Oh, MD | 1 |
| Choe, KW | 1 |
| Catrou, P | 1 |
| Holbert, D | 1 |
| Jones, SL | 1 |
| Nguyen, VK | 1 |
| Nguyen, TM | 1 |
| Athan, E | 1 |
| Sirvent, E | 1 |
| Ruiz, M | 1 |
| Rodríguez, JC | 1 |
| Royo, G | 1 |
| de Cueto, M | 1 |
| Hernández, JR | 1 |
| López-Cerero, L | 1 |
| Morillo, C | 1 |
| Pascual, A | 1 |
| Timmers, GJ | 1 |
| Simoons-Smit, AM | 1 |
| Leidekker, ME | 1 |
| Janssen, JJ | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Huijgens, PC | 1 |
| Leone, S | 1 |
| Fiore, M | 1 |
| Felaco, FM | 1 |
| Esposito, S | 1 |
| Yinusa, W | 1 |
| Onche, II | 1 |
| Thanni, LO | 1 |
| Młynarczyk, G | 1 |
| Młynarczyk, A | 1 |
| Pupek, J | 1 |
| Bilewska, A | 1 |
| Luczak, M | 1 |
| Bennett, KM | 1 |
| Scarborough, JE | 1 |
| Sharpe, M | 1 |
| Dodds-Ashley, E | 1 |
| Hayward, TZ | 1 |
| Vaslef, SN | 1 |
| Vandijck, DM | 1 |
| Decruyenaere, JM | 1 |
| Depuydt, PO | 1 |
| Blot, SI | 1 |
| Saito, R | 1 |
| Okugawa, S | 1 |
| Kumita, W | 1 |
| Sato, K | 1 |
| Chida, T | 1 |
| Okamura, N | 1 |
| Moriya, K | 1 |
| Koike, K | 1 |
| Otter, JA | 1 |
| Klein, JL | 1 |
| Watts, TL | 1 |
| Kearns, AM | 1 |
| French, GL | 1 |
| Putcharoen, O | 1 |
| Suankratay, C | 1 |
| Grundmann, H | 1 |
| Mueller, MR | 1 |
| Hayden, MK | 1 |
| Fridkin, SK | 3 |
| Phillips, L | 2 |
| Lolans, K | 1 |
| Wang, A | 1 |
| Yang, Y | 1 |
| Lu, Q | 1 |
| Chen, Y | 1 |
| Deng, L | 1 |
| Ding, H | 1 |
| Deng, Q | 1 |
| Wang, L | 1 |
| Shen, X | 1 |
| Trzciński, K | 1 |
| Zareba, T | 1 |
| Tyski, S | 1 |
| Hryniewicz, W | 1 |
| Kotilainen, P | 2 |
| Huovinen, P | 2 |
| Eerola, E | 1 |
| García-Rodríguez, JA | 1 |
| Fresnadillo, MJ | 1 |
| García, MI | 1 |
| García-Sánchez, E | 1 |
| García-Sánchez, JE | 1 |
| Trujillano, I | 1 |
| van Tiel, FH | 1 |
| Slangen, BF | 1 |
| Schouten, HC | 1 |
| Jacobs, JA | 1 |
| Dyson, C | 1 |
| Ribeiro, CD | 1 |
| Westmoreland, D | 1 |
| Yu, L | 1 |
| Chen, YL | 1 |
| Zhu, YJ | 1 |
| Coronado, VG | 1 |
| Edwards, JR | 2 |
| Culver, DH | 1 |
| Gaynes, RP | 3 |
| Thornsberry, C | 1 |
| Jumaa, P | 1 |
| Chattopadhyay, B | 1 |
| Beam, TR | 1 |
| Khurana, CM | 1 |
| Wojack, BR | 1 |
| Marshall, SA | 1 |
| Saux, P | 2 |
| Martin, C | 2 |
| Mallet, MN | 2 |
| Papazian, L | 2 |
| Bruguerolle, B | 2 |
| De Micco, P | 1 |
| Gouin, F | 2 |
| Sarkar, S | 1 |
| Singh, M | 2 |
| Narang, A | 1 |
| Cogollos, R | 1 |
| Alós, JI | 1 |
| Gómez-Garcés, JL | 1 |
| Zemelman, R | 2 |
| Bello, H | 2 |
| Dominguez, M | 2 |
| Gonzalez, G | 2 |
| Mella, S | 2 |
| Garcia, A | 2 |
| Pignatari, AC | 1 |
| Hollis, RJ | 1 |
| Leme, I | 1 |
| Fass, RJ | 1 |
| Barnishan, J | 1 |
| Ayers, LW | 1 |
| Huovinen, S | 1 |
| Järvinen, H | 1 |
| Aro, H | 1 |
| Speirs, GE | 1 |
| Fenelon, LE | 1 |
| Reeves, DS | 2 |
| Speller, DC | 1 |
| Smyth, EG | 1 |
| Wilcox, MH | 2 |
| MacGowan, AP | 2 |
| Corti, G | 1 |
| Paradisi, F | 1 |
| Giganti, E | 1 |
| Buffini, G | 1 |
| Tortoli, E | 1 |
| Martelli, L | 1 |
| Pecile, P | 1 |
| Nicoletti, P | 1 |
| Stein, GE | 1 |
| Giamarellos-Bourboulis, EJ | 2 |
| Grecka, P | 2 |
| Giamarellou, H | 2 |
| Molinari, G | 1 |
| Schito, GC | 1 |
| Liu, PY | 1 |
| Lau, YJ | 1 |
| Hu, BS | 1 |
| Shyr, JM | 1 |
| Shi, ZY | 1 |
| Tsai, WS | 1 |
| Lin, YH | 1 |
| Tseng, CY | 1 |
| Turnidge, JD | 1 |
| Nimmo, GR | 1 |
| Francis, G | 1 |
| Porco, FV | 1 |
| Visconte, EB | 1 |
| Marklein, G | 1 |
| Lee, YL | 1 |
| Gupta, G | 1 |
| Cesario, T | 1 |
| Lee, R | 1 |
| Nothvogel, S | 1 |
| Nassar, J | 1 |
| Flionis, L | 1 |
| Thrupp, L | 1 |
| Utili, R | 1 |
| Tripodi, MF | 1 |
| Rosario, P | 1 |
| Andreana, A | 1 |
| Locatelli, A | 1 |
| Rambaldi, A | 1 |
| Florio, A | 1 |
| Udo, EE | 1 |
| al-Obaid, IA | 1 |
| Jacob, LE | 1 |
| Chugh, TD | 1 |
| Jones, EM | 1 |
| Kirkpatrick, BL | 1 |
| Feeney, R | 1 |
| Archibald, L | 1 |
| Monnet, D | 1 |
| McGowan, JE | 3 |
| Tenover, F | 1 |
| Gaynes, R | 1 |
| Cunha, BA | 1 |
| Qadri, SM | 1 |
| Ueno, Y | 1 |
| Walters, EA | 1 |
| Domenico, P | 1 |
| Chuchalin, AG | 1 |
| Novikov, IuK | 1 |
| Avdeev, SN | 1 |
| Belevskiĭ, AS | 1 |
| Majtán, V | 1 |
| Hostacká, A | 1 |
| Pillay, T | 1 |
| Pillay, DG | 1 |
| Adhikari, M | 1 |
| Sturm, AW | 1 |
| Eltahawy, AT | 1 |
| Gimber, EA | 1 |
| Shields, MD | 1 |
| Canawati, HN | 1 |
| Sapico, FL | 1 |
| Krishnaswamy, A | 1 |
| El-Farra, R | 1 |
| Maeder, KN | 1 |
| Montgomerie, JZ | 1 |
| Baiocchi, P | 1 |
| Galiè, M | 1 |
| Santini, C | 1 |
| Carfagna, P | 1 |
| Cassone, M | 1 |
| Tarasi, D | 1 |
| Venditti, M | 1 |
| Sambatakou, H | 1 |
| Chryssouli, Z | 1 |
| Bhat, KG | 2 |
| Paul, C | 1 |
| Ananthakrishna, NC | 1 |
| Ninan, R | 1 |
| Mallya, S | 1 |
| Heggers, JP | 1 |
| Villarreal, C | 1 |
| Edgar, P | 1 |
| Wolf, S | 1 |
| Klein, GL | 1 |
| John, SD | 1 |
| Desai, M | 1 |
| Herndon, DN | 1 |
| Manhold, C | 1 |
| von Rolbicki, U | 1 |
| Brase, R | 1 |
| Timm, J | 2 |
| von Pritzbuer, E | 2 |
| Heimesaat, M | 2 |
| Mombelli, G | 1 |
| Pezzoli, R | 1 |
| Pinoja-Lutz, G | 1 |
| Monotti, R | 1 |
| Marone, C | 1 |
| Franciolli, M | 1 |
| Hershow, RC | 1 |
| Khayr, WF | 1 |
| Schreckenberger, PC | 1 |
| Paladino, JA | 1 |
| Rodríguez Hermosa, JI | 1 |
| Rodríguez Higueras, MI | 1 |
| Sirvent Calvera, JM | 1 |
| García Oria, MJ | 1 |
| Caldwell, JW | 1 |
| Singh, S | 1 |
| Johnson, RH | 1 |
| Filka, J | 2 |
| Huttova, M | 1 |
| Tuharsky, J | 2 |
| Sagat, T | 2 |
| Kralinsky, K | 2 |
| Krcmery, V | 2 |
| Barrett, SP | 1 |
| Threlfall, EJ | 1 |
| Hampton, MD | 1 |
| Cheasty, T | 1 |
| Robert, R | 1 |
| Grollier, G | 1 |
| Doré, P | 1 |
| Hira, M | 1 |
| Ferrand, E | 1 |
| Fauchère, JL | 1 |
| Uher, J | 1 |
| Kurak, H | 1 |
| Novák, I | 1 |
| Urbanová, T | 1 |
| Mateicka, F | 1 |
| Krcméryová, T | 1 |
| Jurga, L | 1 |
| Sulcová, M | 1 |
| Stencl, J | 1 |
| Krúpová, I | 1 |
| Garau, J | 1 |
| Xercavins, M | 1 |
| Rodríguez-Carballeira, M | 1 |
| Gómez-Vera, JR | 1 |
| Coll, I | 1 |
| Vidal, D | 1 |
| Llovet, T | 1 |
| Ruíz-Bremón, A | 1 |
| Ho, M | 1 |
| McDonald, LC | 1 |
| Lauderdale, TL | 1 |
| Yeh, LL | 1 |
| Chen, PC | 1 |
| Shiau, YR | 1 |
| Gilad, J | 1 |
| Borer, A | 1 |
| Peled, N | 1 |
| Riesenberg, K | 1 |
| Tager, S | 1 |
| Appelbaum, A | 1 |
| Schlaeffer, F | 1 |
| Mulazimoglu, L | 1 |
| Casellas, JM | 1 |
| Goossens, H | 1 |
| Von Gottberg, A | 1 |
| Mohapatra, S | 1 |
| Trenholme, GM | 1 |
| Klugman, KP | 1 |
| McCormack, JG | 1 |
| Yu, VL | 2 |
| Orrett, FA | 1 |
| Singh, N | 1 |
| Rogers, P | 1 |
| Atwood, CW | 1 |
| Wagener, MM | 1 |
| Gruson, D | 1 |
| Hilbert, G | 1 |
| Vargas, F | 1 |
| Valentino, R | 1 |
| Bebear, C | 2 |
| Allery, A | 1 |
| Gbikpi-Benissan, G | 1 |
| Cardinaud, JP | 1 |
| Steward, CD | 1 |
| Wallace, D | 1 |
| Hubert, SK | 1 |
| Lawton, R | 1 |
| Tenover, FC | 1 |
| Butkevich, OM | 1 |
| Vinogradova, TL | 1 |
| Torres, A | 1 |
| Bauer, TT | 1 |
| León-Gil, C | 1 |
| Castillo, F | 1 |
| Alvarez-Lerma, F | 1 |
| Martínez-Pellús, A | 1 |
| Leal-Noval, SR | 1 |
| Nadal, P | 1 |
| Palomar, M | 1 |
| Blanquer, J | 1 |
| Ros, F | 1 |
| Lahbabi, MS | 1 |
| Pournaras, S | 1 |
| Slavakis, A | 1 |
| Polyzou, A | 1 |
| Sofianou, D | 1 |
| Maniatis, AN | 1 |
| Tsakris, A | 1 |
| Costa, SF | 1 |
| Newbaer, M | 1 |
| Santos, CR | 1 |
| Basso, M | 1 |
| Soares, I | 1 |
| Levin, AS | 1 |
| Sethi, S | 1 |
| Sharma, M | 1 |
| Ray, P | 1 |
| Gupta, A | 1 |
| Toro, C | 1 |
| García-Samaniego, J | 1 |
| Carbó, J | 1 |
| Iñiguez, A | 1 |
| Alarcón, T | 1 |
| López-Brea, M | 1 |
| Baquero, M | 1 |
| Sánchez-Silos, RM | 1 |
| Pérez-Giraldo, C | 1 |
| Blanco, MT | 1 |
| Morán, FJ | 1 |
| Hurtado, C | 1 |
| Gómez-García, AC | 1 |
| Ratner, AJ | 1 |
| Mosca, RS | 1 |
| Zucker, HA | 1 |
| Trübel, HK | 1 |
| Meyer, HG | 1 |
| Jahn, B | 1 |
| Knuf, M | 1 |
| Kamin, W | 1 |
| Huth, RG | 1 |
| Hill, HA | 1 |
| Volkova, NV | 1 |
| Lawton, RM | 1 |
| Dubois, J | 1 |
| Joly, JR | 1 |
| Witte, W | 1 |
| Grimm, H | 1 |
| Dryden, MS | 1 |
| Talsania, H | 1 |
| McCann, M | 1 |
| Cookson, BD | 1 |
| Phillips, I | 1 |
| Gür, D | 1 |
| Kocagöz, T | 1 |
| Akalin, HE | 1 |
| Ahmad, F | 2 |
| Bray, G | 1 |
| Prescott, RW | 1 |
| Aquilla, S | 1 |
| Lightfoot, NF | 2 |
| Galloway, A | 1 |
| Fabre, D | 1 |
| Bressolle, F | 1 |
| Gomeni, R | 1 |
| Arich, C | 1 |
| Lemesle, F | 1 |
| Beziau, H | 1 |
| Galtier, M | 1 |
| Portet, C | 1 |
| Yoshikawa, TT | 1 |
| Hirata-Dulas, CA | 1 |
| Stein, DJ | 1 |
| Guay, DR | 1 |
| Gruninger, RP | 1 |
| Peterson, PK | 1 |
| Williams, HM | 1 |
| Richards, J | 1 |
| Willocks, LJ | 1 |
| Thompson, C | 1 |
| Emmanuel, FX | 1 |
| Bligh, J | 1 |
| Jones, ME | 1 |
| Scott, AC | 1 |
| Ronald, T | 1 |
| Hanson, M | 1 |
| Morrison, PA | 1 |
| MacLeod, A | 1 |
| Rapp, RP | 1 |
| Billeter, M | 1 |
| Hatton, J | 1 |
| Young, AB | 1 |
| Tibbs, PA | 1 |
| Dempsey, RJ | 1 |
| Schentag, JJ | 3 |
| O'Leary, MP | 1 |
| Doebbeling, BN | 1 |
| Pfaller, MA | 2 |
| Bale, MJ | 1 |
| Wenzel, RP | 2 |
| George, RC | 1 |
| Ball, LC | 1 |
| Norbury, PB | 1 |
| Budnick, LD | 1 |
| Schaefler, S | 1 |
| Shalit, I | 1 |
| Dan, M | 1 |
| Gutman, R | 1 |
| Gorea, A | 1 |
| Berger, SA | 1 |
| Peterson, LR | 1 |
| Quick, JN | 1 |
| Jensen, B | 1 |
| Homann, S | 1 |
| Johnson, S | 1 |
| Tenquist, J | 1 |
| Shanholtzer, C | 1 |
| Petzel, RA | 1 |
| Sinn, L | 1 |
| Gerding, DN | 1 |
| Pennington, JE | 1 |
| Daum, TE | 1 |
| Schaberg, DR | 1 |
| Terpenning, MS | 1 |
| Sottile, WS | 1 |
| Kauffman, CA | 1 |
| Cowden, J | 1 |
| Breitenbucher, RB | 1 |
| Oppenheim, BA | 1 |
| Hartley, JW | 1 |
| Lee, W | 1 |
| Burnie, JP | 1 |
| Peloquin, CA | 2 |
| Cumbo, TJ | 2 |
| Nix, DE | 2 |
| Sands, MF | 2 |
| Brown, RB | 1 |
| Phillips, D | 1 |
| Barker, MJ | 1 |
| Pieczarka, R | 1 |
| Sands, M | 1 |
| Teres, D | 1 |
| Stanley, GL | 1 |
| Mori, M | 1 |
| Scholl, H | 1 |
| Beermann, D | 1 |
| Haverkorn, MJ | 2 |
| Bayer, AS | 1 |
| Simberkoff, MS | 1 |
| Rahal, JJ | 1 |
| Nathan, C | 1 |
| Delzell, D | 1 |
| Kabins, SA | 1 |
| Leigh, DA | 1 |
| Rolston, KV | 1 |
| Alvarez, ME | 1 |
| Hsu, KC | 1 |
| Bodey, GP | 1 |
| Vari, AJ | 1 |
| Vance, JW | 1 |
| Fracasso, JE | 1 |
| Righter, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment[NCT06174519] | 325 participants (Actual) | Observational | 2023-08-01 | Completed | |||
| Risk-factors for Multidrug-resistant (MDR) and Extensively Drug-resistant (XDR) Bacteria Colonization Among Patients at High Risk of STIs[NCT03767374] | 2,186 participants (Actual) | Observational | 2018-05-11 | Active, not recruiting | |||
| The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients[NCT01551186] | Phase 4 | 103 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia : a Randomized Controlled Study (iDIAPASON)[NCT02634411] | 190 participants (Actual) | Interventional | 2016-06-03 | Completed | |||
| A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia[NCT00236834] | Phase 3 | 438 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU)[NCT00410527] | Phase 4 | 0 participants | Interventional | 2006-08-11 | Completed | ||
| Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Reduction of the Duration of Antibiotic Guided by Procalcitonin in Infections Lungs of Hospitalized Elderly: a Randomized[NCT02173613] | 117 participants (Actual) | Interventional | 2012-08-31 | Terminated | |||
| Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Hospitalized Subjects With Pneumonia Requiring Mechanical Ventilation[NCT01570192] | Phase 2 | 43 participants (Actual) | Interventional | 2010-09-30 | Terminated (stopped due to NIAID terminated the study due to low subject enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Colonization of the gastrointestinal tract with C. difficile, vancomycin-resistant enterococci, multidrug-resistant Acinetobacter baumannii, and multidrug- resistant Pseudomonas. Colonization occurs when the subject acquires the above organism while in the study. (NCT01551186)
Timeframe: Participants will be followed while Intubated, an expected average of 7 days. The outcome will be measured 3 days after enrollment and at the end of intubation, average time 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Probiotic | 8 |
| Standard of Care | 8 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| MEGroup - Meropenem Only | 8 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 8 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 2 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 0 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 2 |
Percentage of patients who died by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 3 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 2 |
| ME Group - Meropenem Only | 6 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 2 |
| m-MITT Group - Meropenem Only | 7 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: End of treatment - up to 28 days after enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 3 |
| ME Group - Meropenem Only | 9 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 3 |
| m-MITT Group - Meropenem Only | 11 |
Percentage of patients with successful responses by efficacy endpoint, treatment group and population (n/N) (NCT01570192)
Timeframe: Day 5/Early Extubation
| Intervention | Participants (Count of Participants) |
|---|---|
| ME Group - Meropenem Plus Aminoglycoside | 1 |
| ME Group - Meropenem Only | 1 |
| m-MITT Group - Meropenem Plus Aminoglycoside | 1 |
| m-MITT Group - Meropenem Only | 2 |
The emergence of resistance is defined as a change of meropenem MIC or aminoglycoside MIC by two tube dilutions (fourfold) from baseline when assessed at the second BAL procedure on day 5/early extubation. Patients are evaluable for this endpoint IF they had baseline BAL and Day 5/early extubation and if they had positive cultures on baseline and Day/EE. (NCT01570192)
Timeframe: up to 28 days after enrollment
| Intervention | participants (Number) | |
|---|---|---|
| suppression of emergence of resistance | emergence of resistance | |
| I.V. Meropenem | 5 | 1 |
14 reviews available for ciprofloxacin and Cross Infection
| Article | Year |
|---|---|
Community Acquired Pseudomonas Aeruginosa Pneumonia in a Young Athlete Man: A Case Report and Literature Review.
Topics: Adult; Athletes; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Fatal Outcome; Femal | 2018 |
Evaluation of antimicrobial susceptibility of Enterobacteriaceae causing urinary tract infections in Africa.
Topics: Africa; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Databases, Factual; Drug Ev | 2013 |
[Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end?].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Colistin; Cross Infection; Drug Resistance, Multiple; Humans; | 2010 |
[Proper antibiotic therapy. From penicillin to pharmacogenomic].
Topics: Anti-Bacterial Agents; Bacterial Infections; Cephalexin; Chloramphenicol; Ciprofloxacin; Cross Infec | 2012 |
Infectious keratitis after photorefractive keratectomy.
Topics: Adult; Ciprofloxacin; Corneal Ulcer; Cross Infection; Drug Therapy, Combination; Eye Infections, Bac | 2003 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug | 2004 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; M | 2005 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re | 2006 |
[Bacteria of the genus Arcobacter, a new etiological factor of nosocomial infections].
Topics: Animals; Arcobacter; Bacteriological Techniques; Ciprofloxacin; Cross Infection; Erythromycin; Gram- | 2006 |
[Early and timely therapy: when to interrupt antibiotic therapy in nosocomial acquired pneumonia?].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cohort Studies; Cross Infection; Drug Administration Schedule; | 2007 |
Quinolone therapy in intensive care unit settings.
Topics: Administration, Oral; Aged; Ciprofloxacin; Clinical Protocols; Clinical Trials as Topic; Cross Infec | 1993 |
Hospital-acquired brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review.
Topics: Adult; Anti-Infective Agents; Aztreonam; Ciprofloxacin; Cross Infection; Female; Humans; Microbial S | 2000 |
Approach to therapy of respiratory infections in the critical care setting.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Humans; Inte | 1990 |
Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; Cystic Fibrosi | 1989 |
22 trials available for ciprofloxacin and Cross Infection
| Article | Year |
|---|---|
[Generation of Antibiotic Tolerant Bacterial Persisters in Immunocompromized Patients with Hematologic and Malignant Diseases: A New Problem of Health-Care Associated Infections].
Topics: Adolescent; Anti-Bacterial Agents; Child; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial | 2016 |
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Therapy, Combin | 2003 |
[Antibiotic prophylaxis in transrectal prostate biopsy. Short-term vs. long-term therapy].
Topics: Aged; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofloxacin; Cross Infection; Drug Administration Sc | 2003 |
Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit.
Topics: Bacterial Infections; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2005 |
Clinical effect of intravenous ciprofloxacin on hospital-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bac | 2005 |
Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Blood; | 2006 |
Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cross Infecti | 2007 |
Short-term antibiotic prophylaxis in implant surgery: a comparison of three antibiotics.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ceftriaxone; Cefuroxime; Cip | 2007 |
Epidemiology of the colonization of inpatients and outpatients with ciprofloxacin-resistant coagulase-negative staphylococci.
Topics: Anti-Infective Agents; Carrier State; Ciprofloxacin; Coagulase; Cross Infection; Drug Resistance, Mi | 1995 |
Quinolones in everyday clinical practice: respiratory tract infections and nosocomial pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Double-Blind Method; Female; Fle | 1996 |
[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchitis; Ch | 1997 |
Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study.
Topics: Adult; Anti-Infective Agents; APACHE; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; D | 1998 |
Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, | 1999 |
Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Canada; Ceftazidime; Ci | 1995 |
Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cost-Benefit Analysis; Cross Infection; Double-Blind Me | 1999 |
Emergence and dissemination of quinolone-resistant Escherichia coli in the community.
Topics: Aged; Animals; Animals, Domestic; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Community-Acquir | 1999 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin.
Topics: Adult; Aged; Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Resistance, Mic | 2000 |
A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchitis; Ceftriaxone; Ciprofloxacin; Cross Infecti | 1991 |
Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection.
Topics: Adult; Ceftazidime; Ciprofloxacin; Cross Infection; Double-Blind Method; Drug Evaluation; Humans; Pn | 1991 |
Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Com | 1990 |
Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Cross Infect | 1987 |
261 other studies available for ciprofloxacin and Cross Infection
| Article | Year |
|---|---|
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug R | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cross Infection; Drug Resistance, B | 2007 |
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; be | 2007 |
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
Topics: Bacteremia; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multipl | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; C | 2007 |
Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals.
Topics: Aged; Anti-Bacterial Agents; Canada; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrop | 2007 |
Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals.
Topics: Acinetobacter; Acinetobacter Infections; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; | 2007 |
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactama | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross I | 2007 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; In | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Elect | 2008 |
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acqu | 2008 |
A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; be | 2008 |
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania.
Topics: Academic Medical Centers; Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Base Sequence | 2008 |
Isolation of VanB-type Enterococcus faecalis strains from nosocomial infections: first report of the isolation and identification of the pheromone-responsive plasmids pMG2200, Encoding VanB-type vancomycin resistance and a Bac41-type bacteriocin, and pMG2
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Bacteriocins; Blotting, Southern; Co | 2009 |
Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals.
Topics: Bacterial Proteins; China; Cross Infection; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Geno | 2009 |
Oral and parenteral therapeutic options for outpatient urinary infections caused by enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lac | 2009 |
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
Topics: Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Colistin; Cross Infection; Humans; Molecular | 2009 |
Nonclonal emergence of colistin-resistant Klebsiella pneumoniae isolates from blood samples in South Korea.
Topics: Anti-Bacterial Agents; Bacteremia; Colistin; Cross Infection; Drug Resistance, Bacterial; Humans; Kl | 2010 |
Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems: results from large hospital-based surveillance studies in China.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Carba | 2010 |
Arginine-pyrimidine conjugates with therapeutic and prophylactic activity in lethal bacterial infections.
Topics: Animals; Anti-Bacterial Agents; Arginine; Bacterial Infections; Cross Infection; Drug Interactions; | 2009 |
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Child; Child, Preschool; Cross Infec | 2010 |
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; | 2010 |
Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Ciprofloxacin; Colony Count, Microbial; Cr | 2010 |
Incidence and antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae with extended-spectrum beta-lactamases in community- and hospital-associated intra-abdominal infections in Europe: results of the 2008 Study for Monitoring Antimicrob
Topics: Abdomen; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross Infection; Escherichia coli; Esc | 2010 |
Wide spread and diversity of mutation in the gyrA gene of quinolone-resistant Corynebacterium striatum strains isolated from three tertiary hospitals in China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacteri | 2021 |
Antibacterial effects of Octenicept, and benzalkonium chloride on Acinetobacter baumannii strains isolated from clinical samples and determination of genetic diversity of isolates by RAPD-PCR method.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Benzalkonium Compounds; Ci | 2021 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2020.
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP).
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2022 |
Antibacterial Effects of Henna (Lawsonia inermis) Leaf Extracts (Chloroform) Against Two Food Borne and Nosocomial Infection Causing Pathogens: Staphylococcus aureus and Escherichia coli.
Topics: Anti-Bacterial Agents; Chloroform; Ciprofloxacin; Cross Infection; Escherichia coli; Humans; Lawsoni | 2023 |
Antibacterial Effects of Methanolic Leaf Extracts of Henna (Lawsonia inermis) Against Two Most Common Pathogenic Organisms: Gram Positive Staphylococcus aureus and Gram-Negative Escherichia coli.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Humans; Lawsonia Plant; Met | 2023 |
Antibacterial Effects of Chloroform Henna (Lawsonia inermis) Leaf Extracts against Two Nosocomial Infection Causing Pathogens: Gram-positive Staphylococcus aureus and Gram-negative Klebsiella pneumoniae: A Comparative Study.
Topics: Anti-Bacterial Agents; Chloroform; Ciprofloxacin; Cross Infection; Humans; Klebsiella pneumoniae; La | 2023 |
Ciprofloxacin-resistant ST198 Salmonella Kentucky in a hospitalized American black bear (Ursus americanus), with evidence of subsequent nosocomial transmission.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistan | 2023 |
Epidemiological features, antimicrobial resistance profile and clinical outcomes of healthcare-associated infections in Islamic Republic of Iran.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Delivery of Health Care; Drug Resistance, Bac | 2023 |
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Infection Annual Report 2022.
Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Australia; Bacteremia; Ciprofloxacin; Cross Infe | 2023 |
Tailoring Antibiotic Prophylaxis for Ureteroscopic Procedures Based on Local Resistance Profiles May Lead to Reduced Rates of Infections and Urosepsis.
Topics: Administration, Oral; Adult; Aged; Ampicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprof | 2020 |
Impact of co-existence of PMQR genes and QRDR mutations on fluoroquinolones resistance in Enterobacteriaceae strains isolated from community and hospital acquired UTIs.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cross Infection; Drug Resistance, B | 2019 |
Multidrug-resistant Klebsiella pneumoniae in hospital-acquired infections: Concomitant analysis of antimicrobial resistant strains.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Child; Ciprofloxacin; | 2020 |
Fluoroquinolone resistance conferred by gyrA, parC mutations, and AbaQ efflux pump among Acinetobacter baumannii clinical isolates causing ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carrier Proteins; Ciproflo | 2019 |
Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Chlorpromazine; Ciprofloxa | 2020 |
Predominance of international clone 2 multidrug-resistant Acinetobacter baumannii clinical isolates in Thailand: a nationwide study.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-L | 2021 |
Occurrence of multidrug-resistant Enterococcus faecium isolated from environmental samples.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; DNA, Bacterial; Drug Resista | 2021 |
Repeated exposure of nosocomial pathogens to silver does not select for silver resistance but does impact ciprofloxacin susceptibility.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Humans; Microbial | 2021 |
Clinical features and outcome of Aeromonas sobria bacteremia in pediatric and adult patients with hematologic malignancies: A single-center retrospective study in Peru.
Topics: Adolescent; Adult; Aeromonas; Aged; Bacteremia; Child; Child, Preschool; Ciprofloxacin; Cross Infect | 2021 |
Development of a dried blood spot HPLC-PDA method for the analysis of linezolid and ciprofloxacin in hospital-acquired pneumonia patients.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Dried B | 2017 |
Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Bacteremia; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; | 2017 |
A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis.
Topics: Acute Disease; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ce | 2017 |
Tuning of the Lethal Response to Multiple Stressors with a Single-Site Mutation during Clinical Infection by
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cross Infection; Daptomycin; Gene Expressi | 2017 |
Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection.
Topics: Acinetobacter baumannii; Bacterial Proteins; beta-Lactamases; Carbapenems; Ciprofloxacin; Cross Infe | 2018 |
Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Coinfection; Cross Infection; Drug Resistance, Multiple, Bacte | 2018 |
Meropenem and ciprofloxacin in complicated gastric surgery for cancer patients: A simple SPE-UHPLC-PDA method for their determination in human plasma.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Chromatography, High Pressure Liquid; Ciprofloxacin; | 2019 |
Molecular Characterization of
Topics: Aged, 80 and over; Amino Acid Substitution; Anti-Bacterial Agents; beta-Lactamases; Brazil; Cefepime | 2019 |
Prevalence of the crpP gene conferring decreased ciprofloxacin susceptibility in enterobacterial clinical isolates from Mexican hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cloning, Molecular; C | 2019 |
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cepha | 2020 |
Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; | 2013 |
Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern.
Topics: Ciprofloxacin; Cross Infection; Erythromycin; Gentamicins; Humans; India; Methicillin; Methicillin-R | 2013 |
Helicobacter cinaedi and Helicobacter fennelliae transmission in a hospital from 2008 to 2012.
Topics: Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Cluster Analysis; Cross Infection | 2013 |
Prevalence of plasmid-mediated qnr determinants and gyrase alteration in Klebsiella pneumoniae isolated from a university teaching hospital in Malaysia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Cross Infection; DNA Gyrase; Drug Resistan | 2013 |
Chryseobacterium gleum - a novel bacterium species detected in neonatal respiratory tract infections.
Topics: Chryseobacterium; Ciprofloxacin; Cross Infection; Female; Flavobacteriaceae Infections; Humans; Infa | 2014 |
Potential synergy activity of the novel ceragenin, CSA-13, against carbapenem-resistant Acinetobacter baumannii strains isolated from bacteremia patients.
Topics: Acinetobacter baumannii; Carbapenems; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Dr | 2014 |
[Seven cases of port-a-cath contamination caused by Pantoea agglomerans in the Oncological Service of Iseo Hospital, Brescia (Italy)].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Catheter-Related Infections; Catheterizat | 2014 |
Predictive utility of prior positive urine cultures.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Bacteriuria; Chicago; Ciprofloxacin; Cross | 2014 |
Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Clostridioides difficile; Cross Infection; Drug R | 2014 |
Hepatic cyst infection following aspiration sclerotherapy: a case series.
Topics: Abdominal Pain; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; C | 2014 |
Infectious complications following transrectal ultrasound-guided prostate biopsy: a Canadian tertiary cancer center experience.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cross Infection; Humans; Image-G | 2015 |
Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; China; Ciprofloxacin; Cross Infection; | 2015 |
Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae: interrupted time-series analysis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Cross Infection; Enterobacteriaceae Infection | 2015 |
Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant | 2017 |
Catheter related line sepsis resulting from Mycobacterium chelonae infection in an immunocompromised host.
Topics: Adult; Catheter-Related Infections; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Therapy, Co | 2015 |
Trends of fluoroquinolone-resistant Escherichia coli amongst urinary isolates in children: a 10 year surveillance study.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Community-Acquired Infections; Cross | 2015 |
Outbreak of drug-resistant Acinetobacter baumannii ST219 caused by oral care using tap water from contaminated hand hygiene sinks as a reservoir.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; C | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprof | 2016 |
Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections, with focus on doxycycline.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Clindamycin; Cross Infection; Doxycycline; Drug Resi | 2015 |
No development of ciprofloxacin resistance in the Haemophilus species associated with pneumonia over a 10-year study.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; F | 2015 |
Nitazoxanide Analogues as Antimicrobial Agents Against Nosocomial Pathogens.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; Gram-Positive Endospo | 2016 |
[Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Ciprofloxacin; Cross Infec | 2016 |
Rapid increase in resistance to third generation cephalosporins, imipenem and co-resistance in Klebsiella pneumoniae from isolated from 7,140 blood-cultures (2010-2014) using EARS-Net data in Spain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Bact | 2017 |
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting.
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Cross Infection; Enterococcus faecium; Escherichia | 2016 |
Development of highly biocompatible Gelatin & i-Carrageenan based composite hydrogels: In depth physiochemical analysis for biomedical applications.
Topics: Anti-Bacterial Agents; Bacillus; Carrageenan; Cell Survival; Cells, Cultured; Ciprofloxacin; Cross I | 2016 |
Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection.
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Ceftriaxone; Cefuroxime; Ciprofloxacin; | 2016 |
Antimicrobial Resistance Mechanisms and Genetic Diversity of Multidrug-Resistant Acinetobacter baumannii Isolated from a Teaching Hospital in Malaysia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactamases; Carbapene | 2017 |
Antibiotic resistance in healthcare-related and nosocomial spontaneous bacterial peritonitis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Cross Infection; Drug | 2017 |
Prevalence and antimicrobial susceptibility of Acinetobacter spp. isolated from meat.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Animals; Anti-Bacterial Agents; Cattl | 2017 |
Development and validation of a fast micro-extraction by packed sorbent UHPLC-PDA method for the simultaneous determination of linezolid and ciprofloxacin in human plasma from patients with hospital-acquired pneumonia.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Electrical Equipment and Suppl | 2017 |
Risk factors associated with fluoroquinolone-resistant enterococcal urinary tract infections in a tertiary care university hospital in north India.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Enterococcus; Female; Fluoroquinolones; | 2016 |
Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Hospital Bed Capa | 2008 |
Bacillus cereus nosocomial infection from reused towels in Japan.
Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Bacillus cereus; Bacteremia; Bacterial Toxins; Bedd | 2008 |
Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Ciprofloxa | 2008 |
Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ciprofloxacin; Cross Infection; Data Interpretatio | 2008 |
Antibiotic susceptibility patterns of Pseudomonas aeruginosa to available antipseudomonal drugs in Ibadan, Nigeria.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, | 2008 |
Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Topics: Anti-Infective Agents; Argentina; Biofilms; Ciprofloxacin; Cross Infection; Drug Resistance, Multipl | 2009 |
Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Toxins; Bacterial Typing Techniques; Case- | 2009 |
Fluoroquinolone resistance in clinical and environmental isolates of Escherichia coli in Mexico City.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resist | 2010 |
Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cross Infection; Drug Synergism; Drug | 2008 |
Nosocomial transmission of highly resistant microorganisms on a spinal cord rehabilitation ward.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistan | 2009 |
Ecological effects of selective decontamination on resistant gram-negative bacterial colonization.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Ceftazidime; Ciprofloxacin; Cross Infection; Drug Res | 2010 |
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2010 |
Mechanisms of resistance to ciprofloxacin, ampicillin/sulbactam and imipenem in Acinetobacter baumannii clinical isolates in Taiwan.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; Bacterial Prot | 2010 |
Hospital-acquired pneumonia and bacteremia caused by Legionella pneumophila in an immunocompromised patient.
Topics: Anti-Bacterial Agents; Bacteremia; Ceftazidime; Ciprofloxacin; Clindamycin; Cross Infection; Female; | 2010 |
Nosocomial transmission of Salmonella typhimurium in renal transplant recipients.
Topics: Anti-Bacterial Agents; Bacteriophage Typing; Carrier State; Ciprofloxacin; Cross Infection; Disease | 2010 |
[Dissemination of the KPC carbapenemase producing Klebsiella pneumoniae in a hospital in Warsaw, Poland].
Topics: Adult; Aged; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; | 2010 |
Imipenem and ciprofloxacin consumption as factors associated with high incidence rates of resistant Pseudomonas aeruginosa in hospitals in northern France.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2011 |
Leech-transmitted ciprofloxacin-resistant Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistanc | 2011 |
Surveillance of methicillin-resistant Staphylococcus aureus isolated in Torino (northwest Italy).
Topics: Anti-Bacterial Agents; Bacterial Toxins; Bacterial Typing Techniques; Ciprofloxacin; Community-Acqui | 2011 |
Correlation between fluoroquinolone consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa isolates causing healthcare-associated infections, Taiwan, 2000-2009.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Fluoroquinolones; Hosp | 2011 |
Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Biopsy, Needle; Ciprofl | 2011 |
Activity of vancomycin, ciprofloxacin, daptomycin, and linezolid against coagulase-negative staphylococci bacteremia.
Topics: Acetamides; Bacteremia; Catheter-Related Infections; Ciprofloxacin; Cross Infection; Daptomycin; Dru | 2011 |
[Epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated in the Chugoku region of Japan. Infection Forum in the Chugoku Region].
Topics: Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resis | 2011 |
Nosocomial outbreak of Myroides odoratimimus urinary tract infection in a Tunisian hospital.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Cluster Analysis; Cross Infect | 2012 |
Veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing Klebsiella pneumoniae ST15 clone.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cat Diseases; Cats; Ciprofloxacin; Cross Infection; | 2012 |
Antibacterial activity of Thymus maroccanus and Thymus broussonetii essential oils against nosocomial infection - bacteria and their synergistic potential with antibiotics.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; Cymenes; Drug Synergism | 2012 |
Emergence of Proteus mirabilis harboring blaKPC-2 and qnrD in a Chinese Hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Ciprofloxacin; Clone | 2012 |
Ceftriaxone and ciprofloxacin restriction in an intensive care unit: less incidence of Acinetobacter spp. and improved susceptibility of Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Adult; Aged; Ceftriaxone; Ciprofloxacin; Cross In | 2011 |
[Neonatal infection with Stenotrophomonas maltophilia (2 case studies)].
Topics: Amikacin; Anti-Bacterial Agents; Brain Abscess; Chloramphenicol; Ciprofloxacin; Cross Infection; Dru | 2012 |
Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2012 |
[Prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr among ESBL producing enterobacteria isolates from Chilean hospitals].
Topics: Acetylation; Anti-Bacterial Agents; Bacterial Proteins; Chile; Ciprofloxacin; Cross Infection; Drug | 2012 |
Antimicrobial resistance pattern of gram-negative bacteria of nosocomial origin at a teaching hospital in the Islamic Republic of Iran.
Topics: Acinetobacter; Aged; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multipl | 2012 |
Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome.
Topics: Aged; Ciprofloxacin; Colistin; Colony Count, Microbial; Cross Infection; Drug Resistance, Multiple, | 2012 |
Inhibition of Staphylococcus epidermidis biofilm by trimethylsilane plasma coating.
Topics: Alloys; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Coated Materials, Biocompatible; Cross Infec | 2012 |
Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Ciprofloxa | 2013 |
Nosocomial outbreak of Legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit: evaluation, treatment and control.
Topics: Adult; Bone Marrow Transplantation; Ciprofloxacin; Cross Infection; Decontamination; Disease Outbrea | 2002 |
[Ciprofloxacin in the treatment of hospital-acquired pneumonia: a surveillance study in 676 patients].
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Germany; Humans; I | 2002 |
Ciprofloxacin and Clostridium difficile--associated diarrhea.
Topics: Anti-Infective Agents; Australia; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; C | 2002 |
[Risk factors associated with ceftazidime-resistant Klebsiella pneumoniae infection].
Topics: Aged; Aged, 80 and over; Argentina; Bacterial Proteins; beta-Lactamases; Case-Control Studies; Cefta | 2003 |
Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2003 |
[Bacteremia due to Escherichia coli: epidemiological analysis and sensitivity to antibiotics in a county hospital].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Cross Infection; Drug Resis | 2003 |
[The impact of antibiotic use on hospital-acquired pneumonia: data of etiology tests].
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Ampicillin; Anti-Bacterial Agents; Anti-Infective | 2003 |
[Nosocomial infections caused by Acinetobacter: experience in a neonatal care unit in Casablanca].
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Cip | 2003 |
Detection of a nosocomial outbreak of salmonellosis may be delayed by application of a protocol for rejection of stool cultures.
Topics: Analysis of Variance; Ciprofloxacin; Clinical Protocols; Cohort Studies; Cross Infection; Disease Ou | 2003 |
Carbapenemase-producing Pseudomonas aeruginosa and ciprofloxcacin use in neonatal intensive care units.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Central Nervous System; Ciprofloxacin; C | 2003 |
Prevention of nosocomial lower respiratory tract infections in patients after intracranial artery aneurysm surgery with a short course of antimicrobials.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Female; Humans; Intracranial Aneurysm; Male; | 2003 |
An outbreak of conjunctivitis caused by multiresistant Pseudomonas aeruginosa in a Brazilian newborn intensive care unit.
Topics: Anti-Bacterial Agents; Brazil; Ciprofloxacin; Conjunctivitis; Cross Infection; Disease Outbreaks; Dr | 2003 |
[Necrotizing otitis externa caused by Stenotrophomonas maltophilia].
Topics: Anti-Infective Agents; Bacteriological Techniques; Biopsy; Ciprofloxacin; Cross Infection; Dose-Resp | 2003 |
Evidence for transmission between humans and the environment of a nosocomial strain of Enterococcus faecium.
Topics: Ampicillin Resistance; Animals; Anti-Infective Agents; Bacterial Typing Techniques; Carrier State; C | 2004 |
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients.
Topics: Aged; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection; Female; Fluoroqui | 2003 |
Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections.
Topics: Birth Weight; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Gestatio | 2004 |
[E. coli: resistance to quinolones and beta-lactams of clinical strains isolated in the Franche-Comté region of France].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Ceftazidime; | 2004 |
Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacte | 2004 |
Chryseobacterium meningosepticum infections in a dialysis unit.
Topics: Chryseobacterium; Ciprofloxacin; Cross Infection; Equipment Contamination; Flavobacteriaceae Infecti | 2004 |
Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States.
Topics: Amikacin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Humans; | 2004 |
Nosocomial bloodstream infections with Burkholderia stabilis.
Topics: Adolescent; Adult; Aged; Bacteremia; Bacterial Typing Techniques; Burkholderia; Burkholderia Infecti | 2005 |
[Resistance to gentamicin, amikacin and ciprofloxacin among nosocomial isolates of klebsiella pneumoniae subspecie pneumoniae producing extended spectrum beta-lactamases].
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Ciprofloxa | 2004 |
Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Colony Count, Microbial; Cross Infection; Drug | 2005 |
Temporal changes in bacterial resistance in German intensive care units, 2001-2003: data from the SARI (surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Cross Infection; Drug Resistan | 2005 |
Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2005 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-R | 2005 |
[Postoperative pneumonia: nosocomial, predictable, iatrogenic, preventable or not?].
Topics: Alcoholism; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Carcinoma, Squamo | 2006 |
High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium.
Topics: Base Sequence; Ciprofloxacin; Cross Infection; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Dru | 2006 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluo | 2006 |
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection | 2006 |
Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Cefotaxime; Ciprofloxacin; Community-Acquired Inf | 2006 |
Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; APACHE; Bacteremia; Cephalosporins; Ciprofloxacin; Commu | 2006 |
Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Hospitals, Teaching; Humans; Incidence; Infec | 2006 |
Prevalence of multiresistant Gram-negative organisms in a surgical hospital in Ho Chi Minh City, Vietnam.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cephalosporin Resistance; Ciprofloxacin; Cross Infection; Dr | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Dr | 2006 |
[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; beta-Lactam Resistance; beta-L | 2006 |
[Antibmicrobial susceptibility of Serratia marcescens isolated from hospitalized patients in 2003 - 2005].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Ciprofloxacin; Cross Infec | 2007 |
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infectio | 2007 |
Community-acquired versus nosocomial Klebsiella pneumonia bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance.
Topics: Anti-Bacterial Agents; Bacteremia; Cephalosporins; Ciprofloxacin; Community-Acquired Infections; Cro | 2007 |
Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; | 2007 |
Identification and control of an outbreak of ciprofloxacin-susceptible EMRSA-15 on a neonatal unit.
Topics: Abscess; Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Bacteriological Techniques; | 2007 |
Salmonella gas-forming femoral osteomyelitis and pyomyositis: the first case and review of the literature.
Topics: Acinetobacter Infections; Ceftriaxone; Ciprofloxacin; Clindamycin; Cross Infection; Fatal Outcome; H | 2007 |
Genodiversity of resistant Pseudomonas aeruginosa isolates in relation to antimicrobial usage density and resistance rates in intensive care units.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2008 |
Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Blotting, Western; Case-Control Studies; C | 2008 |
Occurrence of qnr-positive clinical isolates in Klebsiella pneumoniae producing ESBL or AmpC-type beta-lactamase from five pediatric hospitals in China.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Child; Child, Preschool; China; Ciprofl | 2008 |
Comparison of simple methods of methicillin-resistance detection and evaluation of some properties of methicillin-resistant Staphylococcus aureus strains.
Topics: Ciprofloxacin; Cross Infection; Evaluation Studies as Topic; Gentamicins; Humans; Methicillin Resist | 1993 |
Use of gas-liquid chromatography for subgrouping coagulase-negative staphylococci during a nosocomial sepsis outbreak.
Topics: Anti-Infective Agents; Bacteremia; Chromatography, Gas; Ciprofloxacin; Cluster Analysis; Coagulase; | 1995 |
Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bac | 1995 |
Study of Stomatococcus mucilaginosus isolated in a hospital ward using phenotypic characterization.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cluster Analysis; Colony Count, Microbial; Cross Infection; Dr | 1995 |
Large scale use of ciprofloxacin in the control of a Salmonella outbreak in a hospital for the mentally handicapped.
Topics: Ciprofloxacin; Cross Infection; Disease Outbreaks; Female; Hospitals, Psychiatric; Humans; Infection | 1995 |
[Clinical analysis of 60 cases of nosocomal pneumonias].
Topics: Adult; Ciprofloxacin; Cross Infection; Humans; Klebsiella Infections; Klebsiella pneumoniae; Pneumon | 1994 |
Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Pse | 1995 |
Epidemiology of staphylococcal infections--a USA perspective.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Humans; Methicill | 1994 |
Outbreak of gentamicin, ciprofloxacin-resistant Pseudomonas aeruginosa in an intensive care unit, traced to contaminated quivers.
Topics: Ciprofloxacin; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; Equipment Contaminati | 1994 |
Prevalence of ciprofloxacin resistance in multiresistant gram-negative intensive care unit isolates.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Multiple; Gram-Negative Bacterial Infections; Human | 1994 |
Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
Topics: beta-Lactamases; Cefepime; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Ciprofloxacin; Cro | 1994 |
Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.
Topics: Aged; Bronchi; Bronchopneumonia; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infectio | 1994 |
Successful treatment of hospital acquired Klebsiella pneumoniae meningitis in a neonate with ciprofloxacin.
Topics: Ciprofloxacin; Cross Infection; Humans; Infant, Newborn; Klebsiella Infections; Klebsiella pneumonia | 1993 |
[Evolution of fluoroquinolone sensitivity in Staphylococcus aureus isolated from hemocultures in a general hospital].
Topics: Bacteremia; Blood; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hospitals, General; H | 1993 |
Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Chile; Ciprofloxacin; Cross Infection; Drug Resist | 1993 |
Oxacillin- and quinolone-resistant Staphylococcus aureus in Sao Paulo, Brazil: a multicenter molecular epidemiology study.
Topics: Bacterial Typing Techniques; Brazil; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hos | 1993 |
Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Ut | 1995 |
An audit of ciprofloxacin use in a district general hospital.
Topics: Anti-Infective Agents; Bacterial Infections; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Ut | 1995 |
Ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa from Italian patients.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Humans; Italy; Ps | 1995 |
Fluoroquinolone resistance patterns after formulary addition of ofloxacin. A clinical isolate study.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Formularies, Hosp | 1995 |
Comparative in vitro activity of ciprofloxacin vs 8 antimicrobial agents against nosocomial multiresistant P. aeruginosa strains.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple; Greece; Humans; Ph | 1995 |
Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
Topics: Aminoglycosides; Ampicillin Resistance; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Cipr | 1995 |
Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Ciprofloxacin; Cross Infection; Drug Res | 1995 |
Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR).
Topics: Australia; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hospitals, Teaching; Humans; | 1996 |
Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Cross Infection | 1995 |
Colonization by Staphylococcus aureus resistant to methicillin and ciprofloxacin during 20 months' surveillance in a private skilled nursing facility.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; California; Chi-Square Distributi | 1996 |
Different susceptibility of coagulase-positive and coagulase-negative staphylococci to ciprofloxacin.
Topics: Ciprofloxacin; Coagulase; Cross Infection; Drug Resistance, Microbial; Humans; Italy; Methicillin Re | 1996 |
Molecular characterization of epidemic ciprofloxacin- and methicillin-resistant Staphylococcus aureus strains colonizing patients in an intensive care unit.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple; | 1996 |
Hospital-acquired Clostridium difficile diarrhoea.
Topics: Anti-Infective Agents; Cefuroxime; Cephalosporins; Ciprofloxacin; Clostridioides difficile; Cross In | 1997 |
Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Enterococcus; Humans; Imipenem; Intensiv | 1997 |
Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Fluor | 1997 |
Activity of selected beta-lactams, ciprofloxacin, and amikacin against different Acinetobacter baumannii biotypes from Chilean hospitals.
Topics: Acinetobacter; Acinetobacter Infections; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bac | 1997 |
Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
Topics: Alginates; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Depression, | 1996 |
Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cilastatin; Ciprofloxacin; Cross Infection; Drug C | 1998 |
Gram-negative bacilli isolated from patients in intensive care unit: prevalence and antibiotic susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Blood; Carbapenems; Cephalosporins; Ciproflo | 1997 |
Bacteriuria with Escherichia coli resistant to ciprofloxacin in patients with spinal-cord injury.
Topics: Adult; Anti-Infective Agents; Bacteriuria; Case-Control Studies; Ciprofloxacin; Cross Infection; Dis | 1998 |
In vitro susceptibility of Staphylococcus aureus isolated from blood to currently used antistaphylococcal drugs.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Ciprofloxacin; Clindamyci | 1998 |
In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Intera | 1998 |
Drug resistant enterococci in a south Indian hospital.
Topics: Ampicillin; Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Enter | 1998 |
Fluoroquinolone resistant bacteria in nosocomial UTI.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Humans; Incidence | 1998 |
Ciprofloxacin as a therapeutic modality in pediatric burn wound infections: efficacious or contraindicated?
Topics: Adolescent; Age Factors; Anti-Infective Agents; Biopsy; Burns; Child; Child, Preschool; Ciprofloxaci | 1998 |
Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Case-Control Studies; Chicago; Ciprofloxacin; Commun | 1998 |
[Ciprofloxacin neurotoxicity].
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Epilepsy, Generalized; Humans; Male; Middle A | 1999 |
Ten years of ciprofloxacin: the past, present and future. Serious hospital infections. Introduction.
Topics: Anti-Infective Agents; Ciprofloxacin; Clinical Trials as Topic; Cross Infection; Humans | 1999 |
Nosocomial meningitis in children after ventriculoperitoneal shunt insertion.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infe | 1999 |
Molecular epidemiology of multi-resistant Escherichia coli.
Topics: Aged; Anti-Infective Agents; Case-Control Studies; Cephalosporinase; Ciprofloxacin; Cross Infection; | 1999 |
Nosocomial pneumonia with isolation of anaerobic bacteria in ICU patients: therapeutic considerations and outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria, Anaerobic; Cefotaxime; | 1999 |
Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Female; Follow-Up Studies; Humans; Infant; In | 1999 |
Surveillance of antibiotic resistance in Taiwan, 1998.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Enterococcus; Gram-Negative Bacteria; Hu | 1999 |
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.
Topics: Anti-Infective Agents; Bacteremia; beta-Lactamases; Ciprofloxacin; Cross Infection; Drug Resistance, | 2000 |
Methicillin resistance among Trinidadian isolates of community and hospital strains of Staphylococcus aureus and their patterns of resistance to non-beta-lactam antibiotics.
Topics: Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Erythromy | 1999 |
Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria.
Topics: Aged; Antibiotic Prophylaxis; Ceftazidime; Ciprofloxacin; Critical Care; Cross Infection; Cross-Sect | 2000 |
Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug | 2000 |
[Some problems of the current therapy of infective endocarditis].
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infect | 2000 |
[Nosocomial infections in neonatal and pediatric intensive care. The appeal of ciprofloxacin].
Topics: Anti-Infective Agents; Bacterial Infections; Child, Preschool; Ciprofloxacin; Cross Infection; Drug | 2000 |
Nosocomial spread of an unusual methicillin-resistant Staphylococcus aureus clone that is sensitive to all non-beta-lactam antibiotics, including tobramycin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Genotype; | 2001 |
Nosocomial pneumonia: importance of recognition of aetiological agents to define an appropriate initial empirical therapy.
Topics: Anti-Bacterial Agents; Bacteria; Blood; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Cross Infection | 2001 |
Mycobacterium fortuitum wound infection following laparoscopy.
Topics: Amikacin; Ciprofloxacin; Cross Infection; Humans; Laparoscopy; Mycobacterium fortuitum; Mycobacteriu | 2001 |
[Antibiotic therapy. Avoiding resistance].
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Multiple; Germany; Humans; Pseudomonas aeruginosa; | 2001 |
[Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid].
Topics: Adult; Aged; Amoxicillin; Azithromycin; Cefotaxime; Ciprofloxacin; Clarithromycin; Clindamycin; Cros | 2001 |
Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Community-Acquired Infections; Cross In | 2001 |
Citrobacter mediastinitis following cardiac surgery in a neonate.
Topics: Anti-Infective Agents; Cardiac Surgical Procedures; Ciprofloxacin; Citrobacter; Cross Infection; Ent | 2002 |
Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child.
Topics: Anti-Bacterial Agents; Child, Preschool; Ciprofloxacin; Clarithromycin; Cross Infection; Drug Resist | 2002 |
Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Cross Infection; | 2002 |
In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Erythromycin; Humans; In Vitro Technique | 1992 |
Occurrence of quinolone resistance in Staphylococcus aureus from nosocomial infection.
Topics: Anti-Infective Agents; Bacterial Typing Techniques; Ciprofloxacin; Cross Infection; Disease Outbreak | 1992 |
The epidemiology of ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients.
Topics: Air Microbiology; Carrier State; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Health | 1992 |
[In vitro activity of various antibiotic agents against gram-negative nosocomial bacteremia pathogens].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; | 1992 |
Use of ciprofloxacin to control a Salmonella outbreak in a long-stay psychiatric hospital.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross Infection; Diarrhea; Disease Outbreaks; Hospita | 1991 |
Use of ciprofloxacin in the management of Salmonella outbreaks.
Topics: Carrier State; Ciprofloxacin; Cross Infection; Disease Outbreaks; Humans; Infection Control; Salmone | 1991 |
Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchi; Chromatography, High Pressure Liquid; Ciprof | 1991 |
[Diffusion of ciprofloxacin into bronchial secretions in mechanically ventilated patients].
Topics: Aged; Aged, 80 and over; Bronchial Diseases; Ciprofloxacin; Cross Infection; Diffusion; Female; Huma | 1991 |
Treatment of nursing home-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Cross Infection; Homes for the Aged; Humans | 1991 |
Single-dose ciprofloxacin for shigellosis.
Topics: Ciprofloxacin; Cross Infection; Disease Outbreaks; Dysentery, Bacillary; Female; Humans; Shigella so | 1990 |
Hospital outbreak of Salmonella enteritidis infection treated with ciprofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross Infection; Disease Outbreaks; Hospitals, Psychi | 1990 |
Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Cefmenoxime; Ciprofloxacin; Cross Infection; Female; | 1990 |
Economic considerations in management of complicated urinary tract infections.
Topics: Ciprofloxacin; Cost-Benefit Analysis; Cross Infection; Female; Humans; Length of Stay; Middle Aged; | 1990 |
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
Topics: Amikacin; Anti-Infective Agents; Cephalosporins; Ciprofloxacin; Cross Infection; Enterobacteriaceae; | 1990 |
Susceptibility to ciprofloxacin of nosocomial gram-negative bacteria and staphylococci isolated in the UK.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bacteria; Humans; Pseudomo | 1990 |
Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group.
Topics: Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Female; | 1990 |
Cross resistance to ciprofloxacin and other antimicrobial agents among clinical isolates of Acinetobacter calcoaceticus biovar anitratus.
Topics: Acinetobacter; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Cross Infection; Drug Resistance, | 1990 |
Increasing resistance of Staphylococcus aureus to ciprofloxacin.
Topics: Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Humans; Methicillin Resistance; Staphylo | 1990 |
Management of institutional outbreaks of Salmonella gastroenteritis.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Contraindications; Cross Infection; Diarrhea; Disease Outbreak | 1990 |
UTI: managing the most common nursing home infection.
Topics: Activities of Daily Living; Aged; Cefoperazone; Ciprofloxacin; Cross Infection; Female; Homes for th | 1990 |
Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit.
Topics: Cancer Care Facilities; Ciprofloxacin; Coagulase; Cross Infection; Disease Outbreaks; Drug Resistanc | 1989 |
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Topics: Aged; Chromatography, High Pressure Liquid; Ciprofloxacin; Cross Infection; Drug Resistance, Microbi | 1989 |
Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B.
Topics: Administration, Inhalation; Bacterial Infections; Ciprofloxacin; Cross Infection; Disease Outbreaks; | 1989 |
Nosocomial gram-negative bloodstream isolates: a comparison of in vitro antibiotic potency.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactamases; Cefoxitin; Ciprofloxacin; Cross Infect | 1989 |
Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections.
Topics: Bacteria; Ciprofloxacin; Cross Infection; Drug Evaluation; Drug Tolerance; Humans; Infusions, Intrav | 1989 |
Prophylaxis of respiratory tract infection in patients on artificial respiration.
Topics: Amphotericin B; Bronchitis; Ciprofloxacin; Cross Infection; Drug Therapy, Combination; Feces; Female | 1989 |
Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.
Topics: Amikacin; Cefotaxime; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; Humans; Kanamycin; Met | 1986 |
In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
Topics: Aminoglycosides; Anti-Bacterial Agents; Ciprofloxacin; Citrobacter; Cross Infection; Drug Resistance | 1987 |
Ciprofloxacin therapy of respiratory tract infection with Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross Infection; Humans; Middle Aged; Pse | 1988 |
Economic implications of oral treatment replacing parenteral therapy in antimicrobial chemotherapy.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Costs and Cost Analysis; Cross Infection | 1988 |
In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients.
Topics: Anti-Bacterial Agents; Cefepime; Cefpirome; Cephalosporins; Ciprofloxacin; Cross Infection; Fluoroqu | 1986 |
Ciprofloxacin treatment of Staphylococcus aureus infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Ciprofloxacin; Cross Infection; Female; Humans; M | 1987 |